LEE PHARMACEUTICALS
10QSB, 2000-02-11
PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS
Previous: COYOTE NETWORK SYSTEMS INC, SC 13G/A, 2000-02-11
Next: LEGGETT & PLATT INC, SC 13G/A, 2000-02-11



<PAGE>

                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                   FORM 10-QSB

[X]      QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
         EXCHANGE ACT OF 1934
For the quarterly period ended           December 31, 1999
                               -------------------------------------------

                                       OR

[  ]     TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
         EXCHANGE ACT OF 1934

For the transition period from                   to
                               ------------------   -----------------

Commission file number                       1-7335
                        --------------------------------------------------------

                               LEE PHARMACEUTICALS
- --------------------------------------------------------------------------------
        (Exact name of small business issuer as specified in its charter)

        California                                 95-2680312
- --------------------------------        -------------------------------------
(State or other jurisdiction of        (I.R.S. Employer Identification No.)
 incorporation or organization)

            1444 Santa Anita Avenue, South El Monte, California 91733
- --------------------------------------------------------------------------------
                    (Address of principal executive offices)
                                   (Zip Code)

                                 (626) 442-3141
- --------------------------------------------------------------------------------
              (Registrant's telephone number, including area code)

                                      N / A
- --------------------------------------------------------------------------------
      (Former name, former address and former fiscal year, if changed since
                                  last report)

         As of December 31, 1999, there were outstanding 4,135,162 shares of
common stock of the registrant.

         Transitional Small Business Disclosure Format (check one):
Yes            No     X
   ----------    -----------

<PAGE>

                               LEE PHARMACEUTICALS
                                  BALANCE SHEET
                                DECEMBER 31, 1999
                             (DOLLARS IN THOUSANDS)
                                   (UNAUDITED)

<TABLE>
                        ASSETS
<S>                                                                        <C>                 <C>
Cash                                                                                           $           6

Accounts and notes receivable (net of allowances: $157)                                                  988

Due from related party                                                                                   204

Inventories:
     Raw materials                                                         $       1,752
     Work in process                                                                 197
     Finished goods                                                                  458
                                                                           -------------
     Total inventories                                                                                 2,407

Other current assets                                                                                     409
                                                                                               -------------
     Total current assets                                                                              4,014

Property, plant and equipment (less
     accumulated depreciation and
     amortization: $6,211)                                                                               498

Goodwill and other assets, (net of
     accumulated amortization: $6,892)                                                                 3,622
                                                                                               -------------

        TOTAL                                                                                  $       8,134
                                                                                               =============


</TABLE>

                       See notes to financial statements.


<PAGE>


                               LEE PHARMACEUTICALS
                                  BALANCE SHEET
                                DECEMBER 31, 1999
                             (DOLLARS IN THOUSANDS)
                                   (UNAUDITED)

<TABLE>

         LIABILITIES
<S>                                                                                          <C>
Bank overdraft                                                                               $           127
Note payable to bank                                                                                   1,647
Current portion - notes payable, other                                                                 1,571
Current portion - note payable related party                                                             525
Accounts payable                                                                                       1,083
Other accrued liabilities                                                                                710
Environmental cleanup liability                                                                          366
Due to related parties                                                                                   659
Deferred income                                                                                           60
                                                                                             ---------------

         Total current liabilities                                                                     6,748
                                                                                             ---------------

Long-term notes payable to related parties                                                             2,582
                                                                                             ---------------

Long-term notes payable, other                                                                         1,053
                                                                                             ---------------

Environmental cleanup liability - Casmalia Site                                                          374
                                                                                             ---------------


         COMMITMENTS AND CONTINGENCIES

         STOCKHOLDERS' DEFICIENCY

Common stock, $.10 par value; authorized, 7,500,00 shares;
   issued and outstanding, 4,135,162 shares                                                              413

Additional paid-in capital                                                                             4,222

Accumulated deficit                                                                                   (7,258)
                                                                                             ---------------

         Total stockholders' deficiency                                                               (2,623)
                                                                                             ---------------

                  TOTAL                                                                      $         8,134
                                                                                             ===============


</TABLE>

                       See notes to financial statements.


<PAGE>


                               LEE PHARMACEUTICALS

                            STATEMENTS OF OPERATIONS
                (DOLLARS IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)

<TABLE>
<CAPTION>

                                                                                       FOR THE THREE MONTHS
                                                                                        ENDED DECEMBER 31,
                                                                                      1999              1998
                                                                                  -------------    -------------
                                                                                   (UNAUDITED)       (UNAUDITED)
<S>                                                                               <C>             <C>
Gross revenues                                                                    $      2,537     $      2,133
Less:    Sales returns                                                                    (193)            (127)
         Cash discounts and others                                                         (22)             (16)
                                                                                  ------------     ------------

Net revenues                                                                             2,322            1,990
                                                                                  ------------     ------------
Costs and expenses:

       Cost of sales                                                                     1,068              936
       Selling and advertising expense                                                     732              719
       General and administrative expense                                                  305              303
       Interest expense                                                                    216              188
                                                                                  ------------     ------------

Total costs and expenses                                                                 2,321            2,146
                                                                                  ------------     ------------

Income (loss) from operations                                                                1             (156)

Other income                                                                                17               15
                                                                                  ------------     ------------
Net income (loss) before extraordinary item                                                 18             (141)

Extraordinary loss related to Casmalia Disposal Site cleanup                                 -             (374)
                                                                                  ------------     ------------

Net income (loss)                                                                  $        18     $       (515)
                                                                                   ===========     ============

Per share:

       Basic income (loss) per share before extraordinary loss                     $       .00     $       (.03)
       Extraordinary loss                                                                    -             (.09)
                                                                                  ------------     ------------
       Basic income (loss)                                                         $       .00     $       (.12)
                                                                                   ===========     ============


                       See notes to financial statements.

</TABLE>


<PAGE>
                               LEE PHARMACEUTICALS
                            STATEMENTS OF CASH FLOWS
                             (DOLLARS IN THOUSANDS)
<TABLE>
<CAPTION>
                                                                                      FOR THE THREE MONTHS
                                                                                       ENDED DECEMBER 31,
                                                                                      1999              1998
                                                                                ----------------  ---------------
                                                                                    (UNAUDITED)    (UNAUDITED)
<S>                                                                             <C>               <C>
Cash flows from operating activities:
   Net income (loss)..........................................................    $          18    $        (515)
     Loss from extraordinary item.............................................                -              374
                                                                                  -------------    -------------
   Net income (loss) before extraordinary item................................               18             (141)
                                                                                  -------------    -------------
   Adjustments to reconcile net income (loss) to net
    cash provided by operating activities:
   Depreciation...............................................................               35               33
   Amortization of intangibles................................................              220              209
   (Decrease) in deferred income..............................................              (16)             (16)
   (Gain) on disposal of property, plant, and equipment.......................                -                -
Change in operating assets and liabilities:
   (Increase) decrease in accounts receivable.................................              (95)             216
   Decrease (increase) in due from related party..............................                1              (18)
   (Increase) in inventories .................................................              (76)            (181)
   Decrease (increase) in other current assets................................               45              (97)
   (Decrease) increase in accounts payable....................................               (6)             185
   Increase in due to related party...........................................               54               58
   Increase in notes payable, other...........................................              220              740
   Increase (decrease) in other accrued liabilities...........................               54              (34)
   (Decrease) in accrued royalties............................................              (26)            (295)
                                                                                  -------------    -------------
   Total adjustments..........................................................              410              800
                                                                                  -------------    -------------
     Net cash provided by operating activities................................              428              659
                                                                                  -------------    -------------

Cash flows from investing activities:
   Additions to property, plant, and equipment................................             (106)             (21)
   Proceeds from sale of equipment............................................                -                -
   Acquisition of product brands..............................................             (140)            (930)
                                                                                  -------------    -------------
     Net cash (used in) investing activities..................................             (246)            (951)
                                                                                  -------------    -------------

Cash flows from financing activities:

   (Payments on) bank loans...................................................               (6)              (2)
   (Payments on) proceeds from notes payable, other...........................             (209)             326
   Increase (decrease) in bank overdraft......................................               35              (51)
                                                                                  -------------    -------------
     Net cash (used in) provided by financing activities......................             (180)             273
                                                                                  --------------   -------------

Net increase (decrease) in cash...............................................                2              (19)
Cash, beginning of year.......................................................                4               42
                                                                                  -------------    -------------

Cash, end of period...........................................................    $           6    $          23
                                                                                  =============    =============

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:

Cash paid during the year for:
   Interest...................................................................    $         174    $         148
                                                                                  =============    =============

Acquisition of product brands:
   Fair value of assets acquired..............................................    $         340    $       1,015
   Fair value of liabilities incurred.........................................             (200)             (85)
                                                                                   -------------   -------------
     Net cash payments........................................................    $         140    $         930
                                                                                  =============    =============
</TABLE>
                       See notes to financial statements.
<PAGE>

   NOTES TO FINANCIAL INFORMATION

1. Basis of presentation:

   The accompanying balance sheet as of December 31, 1999, and the statements
   of operations and cash flows for the periods ended December 31, 1999, and
   1998, have not been audited by independent accountants but reflect all
   adjustments, consisting of any normal recurring adjustments, which are, in
   the opinion of management, necessary to a fair statement of the results for
   such periods. The results of operations for the three months ended December
   31, 1999, are not necessarily indicative of results to be expected for the
   year ending September 30, 2000.

   Certain information and footnote disclosure normally included in financial
   statements prepared in accordance with generally accepted accounting
   principles have been omitted pursuant to the requirements of the Securities
   and Exchange Commission, although the Company believes that the disclosures
   included in these financial statements are adequate to make the information
   not misleading.

   The financial statements should be read in conjunction with the financial
   statements and notes thereto included in the Company's annual report on
   Form 10-KSB for the fiscal year ended September 30, 1999.

   The Company is involved in various matters involving environmental cleanup
   issues. SEE "Item 2. Management's Discussion and Analysis or Plan of
   Operations" herein and Note 10 of Notes to Financial Statements included in
   the Company's Form 10-KSB for the fiscal year ended September 30, 1999. The
   ultimate outcome of these matters cannot presently be determined.
   Environmental expenditures that relate to an existing condition caused by
   past operations, and which do not contribute to current or future revenue
   generation, are expensed. The Company's proportionate share of the
   liabilities are recorded when environmental remediation and/or cleanups are
   probable, and the costs can be reasonably estimated.

2. Basic income (loss) per share:

   Basic income (loss) per share is based on the weighted average number of
   shares of common stock outstanding during the periods presented. Common
   stock equivalents (common stock options) are not included in the
   calculation for the three months ended December 31, 1999 because the effect
   was immaterial. Common stock equivalents were not included in the loss for
   the three months ended December 31, 1998 because their effect on basic loss
   per share is anti-dilutive. The weighted average number of shares was
   4,135,162 for all periods presented.

3. Note payable to bank:

   Effective April 26, 1996, the Company renewed its real estate loan with the
   bank. The note payable to the bank, secured by deed on land and building,
   requires a monthly payment of $4,200, including interest at the bank's
   reference rate plus 4%, maturing March 2001. At December 31, 1999, the
   interest rate was 12.5%. The note is guaranteed by the former Chairman of
   the Company and the Company's President.

4. Line of credit:

   Effective May 21, 1998, the Company renewed its accounts receivable
   financing, maturing May 2000, whereby 75% of the eligible domestic accounts
   receivable, not to exceed the greater of $1,100,000 or $1,100,000 less
   amounts advanced on inventory, can be advanced. The agreement is renewable
   for successive one year periods thereafter. Also, the agreement requires
   minimum monthly interest of $3,000 with an interest rate of 5% above Bank
   of America's prime rate. The financing agreement includes a $400,000 term
   loan on inventory which is incorporated in the working capital line of
   credit above. This term loan requires monthly payments of $11,110 with an
   interest rate of 6% above Bank of America's prime rate. Additionally, there
   is a separate $440,000 term loan on the Company's equipment. This financing
   is secured by a security interest in all of the Company's assets and
   requires monthly payments of $11,800 including interest at Bank of
   America's prime rate plus 6%.

   On October 29, 1999, the Company and it's asset based financing lender
   mutually agreed to modify the Loan and Security Agreement whereby the
   maximum revolving advance was increased to $1,400,000 from $1,100,000 based
   on domestic accounts receivable. All other terms and conditions of the
   Agreement remain unchanged.
<PAGE>
5. Acquisitions:

   On October 1, 1998, the Company purchased certain assets of the
   Cheracol-Registered Trademark- cough syrup, Comhist-Registered Trademark-
   decongestant tablets and Entuss-Registered Trademark- expectorant product
   lines from Roberts Pharmaceutical Corporation for $684,934. The Company
   remitted $600,000 at closing and is required to make monthly payments of
   $3,538, plus interest at prime, commencing January 1, 1999, and ending
   November 1, 2000. In addition, the Company purchased certain inventory for
   $150,800 for which the Company is required to make monthly payments of
   $6,283, plus interest at prime, commencing January 1, 1999, and ending
   November 1, 2000.

   On December 1, 1998, the Company purchased certain assets of seven
   over-the-counter products from Numark Laboratories, Inc. for $430,000. The
   Company remitted the full $430,000 at closing.

   On April 23, 1999, the Company purchased certain assets of the Lady
   Esther-Registered Trademark- facial cream and powder product line from
   Numark Laboratories, Inc. for $220,000. The Company remitted $220,000 at
   closing. In addition, the Company purchased certain inventory for $169,000.

   On June 29, 1999, the Company purchased certain assets of the
   Take-Off-Registered Trademark-, pre-moistened makeup remover cloths product
   line from Premier Consumer Products, Inc. and Advanced Polymer Systems, Inc.
   for $1,000,000. The Company remitted $200,000 at closing and is required to
   make monthly payments of $32,000 plus interest at prime commencing September
   15, 1999 and ending September 15, 2001. In addition, the Company purchased
   certain inventory for approximately $70,000.

   On November 15, 1999, the Company purchased certain assets of product
   lines from U.S. Dermatologics, Inc. which includes Cope-Registered
   Trademark-, a tension headache relief tablet, and Astring-o-Sol-Registered
   Trademark-, a concentrated mouthwash, for $400,000. The Company has
   remitted $200,000 at closing and is required to make twenty-four equal
   monthly installments of $8,000 plus interest at a rate equal to the
   highest prime rate (published in the Wall Street Journal) during the
   preceding month commencing January 25, 2000 and ending on December 25,
   2001, and a final payment of all remaining principal due on January 25,
   2002. Included in the above purchase price was certain inventories valued
   at approximately $60,000.

ITEM 2.

   MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATIONS

   MATERIAL CHANGES IN RESULTS OF OPERATIONS
   THREE MONTHS ENDED DECEMBER 31, 1999, AND DECEMBER 31, 1998

   Gross revenues for the three months ended December 31, 1999, were
   $2,537,000, an increase of approximately $404,000 or 19% from the
   comparable three months period ended December 31, 1998. The increase in
   gross revenues was due to the added volume generated from the
   Lee-Registered Trademark-Lip-Ex-TM- lip balm line plus the recently
   acquired brands such as: Take-Off-Registered Trademark-, Lady
   Esther-Registered Trademark-, and seven items purchased from Numark
   Laboratories, Inc. These newly acquired brand acquisitions accounted for
   approximately $425,000 or 17% of the Company's total gross revenues. The
   increase in gross revenues was somewhat offset by the reduced sales of the
   nail category products, certain over-the-counter items and depilatories.

   Net revenues increased approximately $332,000 or 17% for the three months
   ended December 31, 1999, as compared to the three months ended December 31,
   1998. The change in net revenues was due to the same explanations discussed
   above. The Company's sales returns increased approximately $66,000 or 52%
   when comparing the three months ended December 31, 1999 and 1998. The
   increase was a result of higher product returns related to prescription
   drug items.

   Cost of sales as a percentage of gross revenues was 42% for the three
   months ended December 31, 1999, compared to 44% for the comparative three
   months period ended December 31, 1998. The lower cost of sales percentage
   was due to a favorable product mix along with longer and more efficient
   production runs.

   Selling and advertising expenses increased $13,000 or 2% when comparing the
   three months ended December 31, 1999, with the three months ended December
   31, 1998. The increase in expenses
<PAGE>
   was mainly due to the following factors; 1) increased amortization expense
   ($33,500), the result of recent brand acquisitions, 2) additional
   cooperative advertising ($48,000), and 3) higher freight costs
   ($47,000). The above increases were offset by decreases in royalty
   expense ($82,000) due to the expiration of the write-off period, lower
   consultant fees ($14,000), and insurance expense ($9,600).

   General and administrative expenses increased $2,000 when comparing the
   three months ended December 31, 1999, with the three months ended December
   31, 1998.

   Interest expense increased $28,000 or 15% when comparing the three months
   ended December 31, 1999, with the three months ended December 31, 1998. The
   increase was due to increased borrowing from the Company's asset based
   financing lender and additional liability commitments as a result of recent
   brand acquisitions. Also, contributing to the increase was a higher prime
   interest rate, 8.5% versus 7.75%, at December 31, 1999 and December 31,
   1998, respectively.

   LIQUIDITY AND CAPITAL RESOURCES

   During the three months ended December 31, 1999, working capital was a
   negative $2,734,000 compared with a negative $2,409,000 as of September
   30,1999. The ratio of current assets to current liabilities was .6 to 1 at
   December 31, 1999, and September 30, 1999. The increase in the Company's
   negative working capital was due to an increase in borrowing on notes
   payable, and increases in notes payable to its asset based financing
   lender.

   The Company has an accumulated deficit of $7,258,000. The Company's past
   recurring losses and the nominal profit from operations in fiscal 1997 and
   the first quarter of fiscal 2000, and inability to generate sufficient cash
   flow from normal operations to meet its obligations as they come due raise
   substantial doubt about the Company's ability to continue as a going
   concern. The Company's ability to continue in existence is dependent upon
   future developments, including retaining current financing and achieving a
   level of profitable operations sufficient to enable it to meet its
   obligations as they become due.

   YEAR 2000 READINESS

   Most companies have computer systems that use two digits to identify a year
   in the date field (e.g. "99" for 1999). These systems must be modified to
   handle turn-of-the century calculations. If not corrected, systems failures
   or miscalculations could occur, potentially causing disruptions of
   operations, including, among other things, the inability to process
   transactions, send invoices, or engage in other normal business activities.
   This creates potential risk for all companies, even if their own computer
   systems are Year 2000 compliant.

   In 1998, the Company initiated a comprehensive review of its computer
   systems to identify processes that could be adversely affected by Year 2000
   issues. In addition, the Company identified computer application systems
   that required modification or replacement. The Company communicated with
   suppliers, vendors, and lenders to determine the extent to which those
   companies are addressing Year 2000 compliance issues.

   The Company currently estimates that the total cost for the Year 2000
   project will be approximately $100,000. During fiscal year 1999, the
   Company incurred approximately $73,000 for charges related to its Year 2000
   remediation effort. The remediation costs include internal labor costs, as
   well as fees and expenses paid to outside contractors specifically
   associated with programming and purchased hardware and upgraded software.
   The Company incurred approximately $13,000 in Year 2000 modication expenses
   during the quarter ended December 31, 1999.

   As of the date of this report, the Company has not experienced any material
   Year 2000 related problems. Based on currently available information,
   management does not believe that the Year 2000 matters discussed above will
   have a material adverse impact on the Company's financial condition or
   results of operations; however, because of the uncertainties in this area,
   no assurances can be given in this regard.

   ENVIRONMENTAL MATTERS

   The Company owns a manufacturing facility located in South El Monte,
   California. The California Regional Water Quality Control Board (The
   "RWQCB") ordered the Company in 1988 and 1989 to
<PAGE>

   investigate the contamination on its property (relating to soil and
   groundwater contamination). The Company engaged a consultant who performed
   tests and reported to the then Chairman of the Company. The Company
   resisted further work on its property until the property upgradient was
   tested in greater detail since two "apparent source" lots had not been
   tested. On August 12, 1991, the RWQCB issued a "Cleanup and Abatement
   Order" directing the Company to conduct further testing and cleanup the
   site. In October 1991, the Company received from an environmental
   consulting firm an estimate of $465,200 for investigation and cleanup
   costs. The Company believed that this estimate was inconclusive and
   overstated the contamination levels. The Company believes that
   subsequent investigations will support the Company's conclusions about
   that estimate. The Company did not complete the testing for the reasons
   listed above as well as "financial constraints". In June 1992 the RWQCB
   requested that the EPA evaluate the contamination and take appropriate
   action. At the EPA's request, Ecology & Environment, Inc. conducted an
   investigation of soil and groundwater on the Company's property. Ecology &
   Environment Inc.'s Final Site Assessment Report, which was submitted to the
   EPA in June 1994, did not rule out the possibility that some of the
   contamination originated on-site, and resulted from either past or current
   operations on the property. The Company may be liable for all or part of
   the costs of remediating the contamination on its property. The EPA has
   not taken any further action in this matter, but may do so in the future.

   The Company and nearby property owners, in consort with their comprehensive
   general liability (CGL) carriers, have engaged a consultant to perform a site
   investigation with respect to soil and shallow groundwater contamination over
   the entire city block. The CGL carriers provided $290,000 in funding which
   paid for the $220,000 study, $20,000 in legal fees for project oversight,
   and a $50,000 balance in the operating fund. Earlier the Company had accrued
   $87,500 as its proportionate share of the earlier quote of $175,000. Since
   that time, the overall scope of the project was increased to $205,000 plus
   $15,000 for waste water disposal, bringing the total to the above listed
   $220,000. The $87,500 accrual was not spent on this project (as the entire
   cost was borne by the CGL carriers), but remains on the books as an accrual
   against the cost of remediation of the same site that was included in the
   study.

   The tenants of nearby properties upgradient have sued the Company alleging
   that hazardous materials from the Company's property caused contamination
   on the properties leased by the tenants. The case name is DEL RAY
   INDUSTRIAL ENTERPRISES, INC. v. ROBERT MALONE, ET AL., Los Angeles County
   Superior Court, Northwest District, commenced August 21, 1991. In this
   action, the plaintiff alleges environmental contamination by defendants of
   its property, and seeks a court order preventing further contamination and
   monetary damages. The Company does not believe there is any basis for the
   allegations and is vigorously defending the lawsuit.

   The Company's South El Monte manufacturing facility is also located over a
   large area of possibly contaminated regional groundwater which is part of
   the San Gabriel Valley Superfund site. The Company has been notified that
   it is a potentially responsible party ("PRP") for the contamination. In
   1995, the Company was informed that the EPA estimated the cleanup costs for
   the South El Monte's portion of the San Gabriel Valley Superfund site to be
   $30 million. The Company's potential share of such amount has not been
   determined. Superfund PRPs are jointly and severally liable for superfund
   site costs, and are responsible for negotiating among themselves the
   allocation of the costs based on, among other things, the outcome of
   environmental investigation.

   In August 1995 the Company was informed that the EPA entered into an
   Administrative Order of Consent with Cardinal Industrial Finishes
   ("Cardinal") for a PRP lead remedial investigation and feasibility study
   (the "Study") which, the EPA states, will both characterize the extent of
   groundwater contamination in South El Monte and analyze alternatives to
   control the spread of contamination. The Company and others have entered
   into the South El Monte Operable Unit Site Participation Agreement with
   Cardinal pursuant to which, among other things, Cardinal will contract with
   an environmental firm to conduct the Study. The Study has been completed.
   The Company's share of the cost of the Study is currently $15,000 and was
   accrued for in the financial statements as of September 30, 1995. The South
   El Monte Operable Unit (SEMOU) participants developed four remedial
   alternatives. The capital cost of the four alternatives range from $0 (no
   action) up to $3.49 million. The estimated annual operating cost of the
   four alternatives range from $0 (no action) to $770,300. Over a 30-year
   period, the total cost of the four alternatives range from $0 (no action)
   up to $13.05 million. The EPA prefers an alternative which estimates the
   capital cost up to $3.08 million, the annual operating cost at $.48
   million, and the 30-year period total cost up to approximately $9.09
   million. The selection of the actual alternative implemented is subject to
   public comment. At the present time, the Company does not know what its
   share of the cost may be, if any. Therefore, no additional accrual has been
   recognized as a liability on the Company's books.

<PAGE>

   The City of South El Monte, the city in which the Company has its
   manufacturing facility, is located in the San Gabriel Valley. The San
   Gabriel Valley has been declared a Superfund site. The 1995 Water Quality
   Control Plan issued by the California Regional Water Quality Control Board
   states that the primary groundwater basin pollutants in the San Gabriel
   Valley are volatile organic compounds from industry, nitrates from
   subsurface sewage disposal and past agricultural activities. In addition,
   the Plan noted that hundreds of underground storage tanks leaking gasoline
   and other toxic chemicals have existed in the San Gabriel Valley. The
   California Department of Toxic Substance Control have declared large areas
   of the San Gabriel Valley to be environmentally hazardous and subject to
   cleanup work.

   The Company believes the City of South El Monte does not appear to be
   located over any of the major plumes. However, the EPA recently announced
   it is studying the possibility that, although the vadose soil and
   groundwater, while presenting cleanup problems, there may be a
   contamination by DNAPs (dense non-aqueous phase liquids), i.e., "sinkers",
   usually chlorinated organic cleaning solvents. The EPA has proposed to
   drill six "deep wells" throughout the City of South El Monte at an
   estimated cost of $1,400,000. The EPA is conferring with SEMPOA (South El
   Monte Property Owners Association) as to cost sharing on this project.
   SEMPOA has obtained much lower preliminary cost estimates. The outcome cost
   and exact scope of this are unclear at this time.

   The Company and other property owners engaged Geomatrix Consultants, Inc.,
   to do a survey of vadose soil and shallow groundwater in the "hot spots"
   detected in the previous studies. Geomatrix issued a report dated December
   1, 1997 (the "Report"), on the impact of volatile organic compounds on the
   soil and groundwater at the Lidcombe and Santa Anita Avenue site located in
   South El Monte, California (which includes the Company's facilities). The
   Report indicated generally low concentrations of tetrachloroethene,
   trichloaethene and trichloroethane in the groundwater of the upgradient
   neighbor. The Report was submitted to the RWQCB for its comments and
   response. A meeting with the parties and RWQCB was held on February 10,
   1998. The RWQCB had advised companies that vadose soil contamination is
   minimal and requires no further action. However, there is an area of
   shallow groundwater which has a higher than desired level of chlorinated
   solvents, and the RWQCB requested a proposed work plan be submitted by
   Geomatrix. Geomatrix has submitted a "Focused Feasibility Study" which
   concludes that there are five possible methods for cleanup. The most
   expensive are for a pump and sewer remediation which would cost between
   $1,406,000 and $1,687,000. The Company is actively exploring the less
   expensive alternative remediation methods, of which the two proposed
   alternatives range in cost between $985,000 and $1,284,000. Accordingly,
   the Company has taken the average of the two amounts ($985,000 and
   $1,284,000) as the total amount of estimated cost. Since there are four
   economic entities involved, the Company's best estimate at this time, in
   their judgment, would be that their forecasted share would be 25% or
   $284,000 less the liability already recognized on the books of $162,000
   thereby requiring an additional $122,000 liability. Accordingly, the
   Company recorded an additional accrual of $122,000 in the third quarter of
   fiscal 1998. The $122,000 accrual is in addition to the $79,000 accrual for
   the Monterey Site as will be explained in the following paragraph. The
   $79,000 accrual, in the third quarter of fiscal 1998, related to the
   Monterey Site is not included in the $284,000 figure above. No assurances
   can be given that any of the alternative remediation methods will be
   feasible or that the actual cost to the Company of the remediation will not
   exceed the amount of the Company's current accruals of $284,000 (which
   includes the $122,000 charge to income in the third quarter of fiscal
   1998).

   Without any prior correspondence or inkling of the Company's potential
   liability, the EPA has recently informed the Company that the Company may
   have potential liability for the ongoing remediation of Operating
   Industries, Inc. (as they have gone out of business) Landfill Superfund
   Site in Monterey Park, California (the "Monterey Site"). The Monterey Site
   is a 190 acre landfill that operated from 1948 to 1984, in which the
   Company disposed of non toxic pH balanced waste water on six occasions
   between 1974 and 1978. Over 4,000 companies have been identified as having
   contributed waste to the Monterey Site. The EPA has offered to settle the
   Company's potential liability with respect to the Monterey Site for a cost
   to the Company of $79,233. The Company accrued a $79,000 charge in the
   third quarter of fiscal 1998 with respect to this possible liability. The
   Company has elected to file for relief from these obligations under the
   financial hardship option in the EPA's response form.

   The Company has been notified by the EPA that the Company may have
   potential liability for waste material it disposed of at the Casmalia
   Disposal Site ("Site") located on a 252-acre parcel in Santa Barbara
   County, California. The Site was operational from 1973 to 1989 and over
   10,000 separate

<PAGE>

   parties disposed of waste there. The EPA stated that federal, state and
   local governmental agencies along with the numerous private entities that
   used the Site for waste disposal will be expected to pay their share as part
   of this settlement. The U.S. EPA is also pursuing the owner(s)/operator(s) of
   the Site to pay for Site remediation. The EPA has a settlement offer to the
   Company with respect to the Site for a cost of $373,950. The Company accrued
   a $374,000 charge in the first quarter of fiscal 1999 with respect to this
   possible liability. The Company has elected to file for relief from these
   obligations under the financial hardships option in the EPA's response form.

   The total amount of environmental investigation and cleanup costs that the
   Company may incur with respect to the foregoing is not known at this time.
   However, based upon information available to the Company at this time, the
   Company has expensed since 1988 a total of $860,000, of which $89,000 were
   legal fees, exclusive of legal fees expended in connection with the SEC
   environmental investigation. The actual costs could differ materially from
   the amounts expensed for environmental investigation and cleanup costs to
   date.

<PAGE>

                           PART II - OTHER INFORMATION

Item 1.       Legal Proceedings

The information set forth under Part I, Item 2, "Management's Discussion and
Analysis or Plan of Operations - Environmental Matters" is incorporated herein
by reference. SEE ALSO "Legal Proceedings" in the Company's Form 10-KSB for the
fiscal year ended September 30, 1999.

Item 6.       The following exhibits are filed herewith:

              10.1    Promissory note evidencing advance made to the Registrant

              10.2    Modification of loan and security agreement dated
                      October 29, 1999, between Lee Pharmaceuticals and Finova
                      Capital Corporation (formerly Preferred Business Credit,
                      Inc.) regarding a revolving credit facility financing

              10.3    Modification of secured (by inventory) promissory note
                      dated October 29, 1999, between Lee Pharmaceuticals and
                      Finova Capital Corporation (formerly Preferred Business
                      Credit, Inc.)

              10.4    Modification of secured (by equipment) promissory note
                      dated October 29, 1999, between Lee Pharmaceuticals and
                      Finova Capital Corporation (formerly Preferred Business
                      Credit, Inc.)

               27     -    Financial Data Schedule

              The following exhibits have previously been filed by the Company:

               3.1    -    Articles of Incorporation, as amended  (1)

               3.4    -    By-laws, as amended December 20, 1977  (2)

               3.5    -    Amendment of By-laws effective March 14, 1978  (2)

               3.6    -    Amendment to By-laws effective November 1, 1980  (3)

              (1)     Filed as an Exhibit of the same number with the Company's
                      Form S-1 Registration Statement filed with the Securities
                      and Exchange Commission on February 5, 1973, (Registrant
                      No. 2-47005), and incorporated herein by reference.

              (2)     Filed as Exhibits 3.4 and 3.5 with the Company's
                      Form 10-K Annual Report for the fiscal year ended
                      September 30, 1978, filed with the Securities and Exchange
                      Commission and incorporated herein by reference.

              (3)     Filed as an Exhibit of the same number with the Company's
                      Form 10-K Annual Report for the fiscal year ended
                      September 30, 1979, filed with the Securities and Exchange
                      Commission and incorporated herein by reference.


<PAGE>


                                   SIGNATURES

   In accordance with the requirements of the Securities Exchange Acts of 1934,
   the registrant has caused this report to be signed on its behalf by the
   undersigned thereunto duly authorized.

                                                   LEE PHARMACEUTICALS
                                                   -------------------
                                                       (Registrant)



  Date:     February 9, 2000                    /s/ RONALD G. LEE
         ----------------------          --------------------------------------
                                                   Ronald G. Lee
                                          Chairman of the Board, President and
                                         Chief Financial and Accounting Officer





<PAGE>



                                                                   EXHIBIT 10.1
                                                                    Page 1 of 1



- -------------------------------------------------------------------------------



                                 STRAIGHT NOTE




     $200,000          South El Monte, California         November 11, 1999
- -----------------


         For value received, Lee Pharmaceuticals promises to pay Mark DiSalvo
or order, at South El Monte, California the sum of TWO HUNDRED THOUSAND
DOLLARS, with interest from November 11, 1999, on unpaid principal at the
rate of twenty (20) per cent per annum; principal is payable monthly,
commencing on December 25, 1999, with monthly principal payments of $10,000.
Interest shall be calculated on the basis of the unpaid principal balance
daily, based on a 365-day year, actual day month and payable monthly.
Principal and interest shall be payable in lawful money of the United States.
If action were instituted on this note, I promise to pay such sum as the
Court may fix as attorney's fees. This note is secured by the following
trademarks; Cope and Astring-o-Sol.

        11/29/99                     /s/ Ronald G. Lee
- --------------------           --------------------------------------
         Date                  Lee Pharmaceuticals - Ronald G. Lee

        11/24/99                     /s/ Michael L. Agresti
- --------------------           ------------------------------------------------
         Date                  Lee Pharmaceuticals - Michael L. Agresti

- -------------------------------------------------------------------------------


<PAGE>

                                                                    EXHIBIT 10.2


                                                                   [LOGO]






                               LOAN AND SECURITY AGREEMENT

                                   LEE PHARMACEUTICALS

                                       Borrower
                               1444 Santa Anita Avenue,
                               South El Monte, CA 91733

                                        Address
                                      95-2680312

                                Borrower Fed ID Tax No.


                                     $1,400,000.00

                                      Credit Limit

                                    October 29, 1999

                                          Date





         ----------------------------------------------------------------------

                                 FINOVA GROWTH FINANCE

         ----------------------------------------------------------------------





         April 1999


<PAGE>

<TABLE>
<CAPTION>

                                    TABLE OF CONTENTS
   <S>                                                                       <C>
   1. DEFINITIONS AND CONSTRUCTION........................................... 1
      1.1    Definitions .................................................... 1
      1.2    Accounting Terms ............................................... 4
      1.3    Code  .......................................................... 5
      1.4    Construction ................................................... 5
      1.5    Exhibits  ...................................................... 5

   2. LOANS; INTEREST RATE AND OTHER CHARGES................................. 5
      2.1    Revolving Advances  ............................................ 5
      2.2    Term Loan  ..................................................... 5
      2.3    Overadvance  ................................................... 5
      2.4    Interest: Rate; Payments; and Calculation  ..................... 5
      2.5    Crediting Payments  ............................................ 6
      2.6    Statements of Obligations ...................................... 6
      2.7    Fees  .......................................................... 6
      2.8    Term; Automatic Renewal  ....................................... 7
      2.9    Effect of Termination  ......................................... 7
      2.10   Early Termination by Borrower  ................................. 7
      2.11   Termination Upon Event of Default  ............................. 7

   3. SECURITY............................................................... 7
      3.1   Grant of Security Interest  ..................................... 8
      3.2   Negotiable Collateral  .......................................... 8
      3.3   Collection of Accounts, Negotiable Collateral  .................. 8
      3.4   Delivery of Additional Documentation Required  .................. 8
      3.5   Power of Attorney  .............................................. 8
      3.6   Right To Inspect  ............................................... 8

   4. CONDITIONS OF CLOSING.................................................. 8
      4.1   Initial Advance.................................................. 8
      4.2   Subsequent Advances.............................................. 9

   5. REPRESENTATIONS AND WARRANTIES......................................... 9
      5.1   No Prior Encumbrances............................................ 9
      5.2   Bona Fide Accounts............................................... 9
      5.3   Merchantable Inventory and Inventory Records..................... 9
      5.4   Location of Inventory and Equipment.............................. 9
      5.5   Location of Principal Place of Business/Chief Executive
            Office/Residence................................................. 9
      5.6   Due Organization and Qualification............................... 9
      5.7   Due Authorization; No Conflict  ................................ 10
      5.8   Litigation  .................................................... 10
      5.9   No Material Adverse Change in Financial Statements ............. 10
      5.10  Solvency  ...................................................... 10
      5.11  ERISA  ......................................................... 10
      5.12  Environmental Condition ........................................ 10
      5.13  Reliance by FINOVA; Cumulative.................................. 11
      5.14  Year 2000 Representations & Warranties.......................... 11




                                     Page I


<PAGE>

  <S>                                                                       <C>
   6. COVENANTS............................................................. 11
      6.1   Affirmative Covenants
            6.1.1  Accounting System........................................ 11
            6.1.2  Collateral Reports....................................... 11
            6.1.3  Assignments of Accounts.................................. 11
            6.1.4  Financial Statements, Reports, Certificates.............. 11
            6.1.5  Tax Returns, Receipts.................................... 12
            6.1.6  Guarantor Reports........................................ 12
            6.1.7  Designation of Inventory and Returns..................... 12
            6.1.8  Title to Equipment....................................... 12
            6.1.9  Maintenance of equipment................................. 12
            6.1.10 Taxes.................................................... 13
            6.1.11 Insurance................................................ 13
            6.1.12 FINOVA Expenses.......................................... 13
            6.1.13 Year 2000 Covenants...................................... 13

      6.2   Negative Covenants  ............................................ 13
            6.2.1  Extraordinary Transactions and Disposal of Assets........ 13
            6.2.2  Change Name.............................................. 14
            6.2.3  Merge, Acquire........................................... 14
            6.2.4  Guarantee................................................ 14
            6.2.5  Restructure.............................................. 14
            6.2.6  Prepayment............................................... 14
            6.2.7  Change of Ownership...................................... 14
            6.2.8  Capital Expenditures..................................... 14
            6.2.9  Consignments ............................................ 14
            6.2.10 Distributions............................................ 14
            6.2.11 Accounting Methods....................................... 14
            6.2.12 Investments ............................................. 14
            6.2.13 Transactions with Affiliates ............................ 14

   7. DEFAULTS AND REMEDIES................................................. 15
      7.1  Defaults......................................................... 15
      7.2  Remedies         ................................................ 16
      7.3  Remedies Cumulative  ............................................ 17

   8. EXPENSES AND INDEMNITIES.............................................. 17

   9. MISCELLANEOUS......................................................... 18
      9.1   Demand; Protest; etc.   ........................................ 18
      9.2   FINOVA's Liability for Inventory or Equipment................... 18
      9.3   NOTICES......................................................... 18
      9.4   CHOICE OF LAW AND VENUE; JURY TRIAL WAIVER...................... 19
      9.5   DESTRUCTION OF BORROWER'S DOCUMENTS............................. 19
      9.6   Effectiveness  ................................................. 19
      9.7   Successors and Assigns  ........................................ 19
      9.8   Section Headings  .............................................. 19
      9.9   Interpretation  ................................................ 19
      9.10  Publicity         .............................................. 20
      9.11  Severability of Provisions  .................................... 20
      9.12  Amendments in Writing  ......................................... 20
      9.13  Counterparts   ................................................. 20

</TABLE>

                                     Page II

<PAGE>

This LOAN AND SECURITY AGREEMENT, is entered into as of October 29, 1999,
between FINOVA CAPITAL CORPORATION, a Delaware corporation ("FINOVA"),
located at 355 South Grand Avenue, Suite 2400, Los Angeles, California 90071,
and LEE PHARMACEUTICALS ("Borrower") located at 1444 Santa Anita Avenue,
South El Monte, CA 91733.

     The parties agree as follows:

     1.  DEFINITIONS AND CONSTRUCTION

         1.1  DEFINITIONS.  As used this Agreement, the following terms shall
have the following definitions:

              "Accounts" means all presently existing and hereafter arising
accounts, contract rights, and all other forms of obligations owing to
Borrower arising out of the sale or lease of goods or the rendition of
services by borrower, whether or not earned by performance, and any and all
credit insurance, guaranties, and other security therefor, as well as all
merchandise returned to or reclaimed by borrower and borrower's books
relating to any of the foregoing.

              "Agreement" means this Loan And Security Agreement and any
extensions, riders, supplements, notes, amendments, or modifications to or in
connection with this Loan And Security Agreement. This Loan and Security
Agreement amends and supercedes that Loan and Security Agreement dated May
21, 1996.

              "Authorized Officer" means any officer of Borrower authorized
in writing to transact business with FINOVA.

              "Base Rate" means the variable rate of interest, per annum,
most recently announced by CITIBANK N.A., (or any successor thereto), from
time to time as its "base rate", which may not be such institution's lowest
rate (the "Base Rate"), with the understanding that the "Base rate" merely
serves as a basis upon which effective rates of interest are calculated for
loans making reference thereto and may not be the lowest or best rate
available from such financial institution.

              "Borrower's Books" means all of the Borrower's books and
records including: ledgers; records indicating, summarizing, or evidencing
Borrower's assets or liabilities, or the Collateral; all information relating
to Borrower's business operations or financial condition; and all computer
programs, disk or tape files, printouts, runs, or other computer prepared
information, and the equipment containing such information.

              "Borrowing Base" has the meaning set forth in Section 2.1.

              "Business Day" means any day, which is not a Saturday, Sunday,
or other day on which banks in the state of California are authorized or
required to close.

              "Code" means the California Uniform Commercial Code.

              "Collateral" means each of the following: the Accounts; the
Equipment; the General Intangibles; the Inventory; the Negotiable Collateral;
the Investment Property; any money, or other assets of Borrower which
hereafter come into the possession, custody, or control of FINOVA and the
proceeds and products, whether tangible or intangible, of any of the
foregoing, including proceeds of insurance covering any or all of the
Collateral, and any and all Accounts, Equipment, General Intangibles,
Investment Property, Negotiable Collateral, money, deposit accounts, or other
tangible or intangible property resulting from the sale or other disposition
of the Collateral, or any portion thereof or interest therein, and the
proceeds thereof.

                                       1

<PAGE>

              "Daily Balance" means the amount of the Obligations owed by
Borrower at the end of a given day.

              "Eligible Accounts" means those Accounts created by Borrower in
the ordinary course of business arising out of Borrower's sale of goods or
rendition of services, which have been validly assigned and strictly comply
with all of Borrower's representations and warranties to FINOVA, and which
are and at all times shall continue to be acceptable to FINOVA in all
respects; PROVIDED, HOWEVER, that standards of eligibility may be fixed and
revised from time to time by FINOVA in FINOVA's exclusive judgment. Eligible
Accounts shall not include the following:

              (a)  Accounts which the account debtor has failed to pay within
NINETY (90) days of invoice date;

              (b)  Accounts with selling terms of more than thirty (30) days;

              (c)  Accounts with respect to which the account debtor is an
officer, employee, or agent of Borrower;

              (d)  Accounts with respect to which goods are placed on
consignment, guaranteed sale, sale or return, sale on approval, bill and
hold, or other terms by reason of which the payment by the account debtor may
be conditional;

              (e)  Accounts with respect to which the account debtor is not a
resident of the United States, and which are not either (1) covered by credit
insurance in form and amount, and by an insurer, satisfactory to FINOVA, or
(2) supported by one or more letters of credit in favor of FINOVA as
co-beneficiary, in an amount and of a tenor, and issued by a financial
institution, acceptable to FINOVA;

              (f)  Accounts with respect to which the account debtor is the
United States or any department, agency, or instrumentality of the United
States, any State of the United States, or any city, town, municipality, or
division thereof;

              (g)  Accounts with respect to which the account debtor is a
subsidiary of, related to, affiliated with or has common shareholders,
officers or directors with Borrower;

              (h)  Accounts with respect to which Borrower is or may become
liable to the account debtor for goods sold or services rendered by the
account debtor to Borrower;

              (i)  Accounts with respect to an account debtor whose total
obligations to Borrower exceed ten percent (10%) of all Eligible Accounts to
the extent such obligations exceed the aforementioned percentage;

              (j)  Accounts with respect to which the account debtor disputes
liability or makes any claim with respect thereto, or is subject to any
insolvency proceeding, or becomes insolvent, fails, or goes out of business;
and

              (k)  Accounts the collection of which FINOVA believes to be
doubtful by reason of the account debtor's financial condition.

              "Eligible Inventory" means Inventory consisting of first
quality finished goods held for resale in the ordinary course of Borrower's
business and raw materials for such finished goods, which are located at
Borrower's premises and acceptable to FINOVA in all respects. Eligible
Inventory shall not include work in process, components which are not part of
finished goods, spare parts, packaging and Shipping materials, supplies used
or consumed in Borrower's business, Inventory at the premises of third
parties or subject to a security interest or lien in favor of any third
party, bill and hold goods, inventory


                                      2
<PAGE>

which is not subject to FINOVA's perfected security interest, returned and/or
defective goods, "seconds" and Inventory purchased on consignment. Eligible
Inventory shall be valued at the lower of Borrower's cost or market.

         "Equipment" means all of Borrower's present and hereafter acquired
machinery, machine tools, motors, equipment, furniture, furnishings,
fixtures, motor vehicles, tools, parts, dies, jigs, goods (other than
consumer goods or farm products), and any interest in any of the forgoing,
and all attachments, accessories, accessions, replacements, substitutions,
additions, and improvements to any of the forgoing, wherever located.

         "ERISA" means the Employee Retirement Income Security Act of 1974,
as amended, and the regulations thereunder.

         "ERISA" Affiliate" means each trade or business (whether or not
incorporated and whether or not foreign) which is or may hereafter become a
member of a group of which Borrower is a member and which is treated as a
single employer under ERISA Section 4001(b)(1), or IRC Section 414.

         "FINOVA Expenses" means all: costs or expenses (including taxes and
insurance premiums) required to be paid by Borrower under any of the Loan
Documents which are paid or advanced by FINOVA: filing, recording,
publication, appraisal, and search fees paid or incurred by FINOVA in
connection with FINOVA's transactions with Borrower; costs and expenses
incurred by FINOVA in the disbursement of funds to Borrower (by wire
transfer or otherwise); charges resulting from the dishonor of checks; costs
and expenses incurred by FINOVA to correct any default or enforce any
provision of the Loan Documents, or in gaining possession of, maintaining,
handling, preserving, storing, shipping, selling, preparing for sale, or
advertising to sell the Collateral, or any portion thereof, whether or not a
sale is consummated; costs and expenses of auditing Borrower; costs and
expenses of third party claims or any suit incurred by FINOVA in enforcing or
defending the Loan Documents; and FINOVA's reasonable attorney's fees and
expenses incurred in advising, structuring, drafting, reviewing,
administering, amending, terminating, enforcing, defending, or concerning the
Loan Documents, whether or not suit is brought.

         "GAAP" means generally accepted accounting principles as in effect
from time to time.

         "General Intangibles" means all of Borrower's present and future
general intangibles and other personal property (including choses or things
in action, goodwill, patents, trade names, trademarks, servicemarks,
copyrights, blue prints, drawings, purchase orders, customer lists, monies
due or recoverable from pension funds, route lists, monies due under any
royalty or licensing agreements, infringement claims, computer programs,
computer discs, computer tapes, literature, reports, catalogs, deposit
accounts, insurance premium rebates, tax refunds, and tax refund claims)
other than goods and Accounts, and Borrower's Books relating to any of the
foregoing.

         "Insolvency Proceeding" means any proceeding commenced by or against
any person or entity under any provision of the United States Bankruptcy
Code, as amended, or under any other bankruptcy or insolvency law, including
assignments for the benefit of creditors, formal or informal moratoria,
compositions, or extensions generally with its creditors.

         "Inventory" means all present and future inventory in which borrower
has any interest, including goods held for sale or lease or to be furnished
under a contract of service and all of Borrower's present and future raw
materials, work in process, finished goods, and packaging and shipping
materials, wherever located, and any documents of title representing any of
the above, and Borrower's books relating to any of the foregoing.

                                      3
<PAGE>

         "Investment Property" means all of Borrower's presently existing and
hereafter acquired or arising investment property (as that term is defined in
Section 9115 of the Code).

         "IRC" means the Internal Revenue Code of 1986, as amended, and
regulations thereunder.

         "Judicial Officer or Assignee" means any trustee, receiver,
controller, custodian, assignee for the benefit of creditors, or any other
person or entity having powers or duties like or similar to the powers and
duties of a trustee, receiver, controller, custodian, or assignee for the
benefit of creditors.

         "Loan Documents" means, collectively, this Agreement, any note or
notes (including the term note) executed by Borrower to the order of FINOVA,
and any other agreement entered into between Borrower and FINOVA in
connection with this Agreement.

         "Multiemployer plan" means a "multiemployer plan" as defined in
ERISA Section 3(37) or 4001(a)(3) or IRC Section 414(f), which covers
employees of the Borrower of any ERISA Affiliate.

         "Negotiable Collateral" means all of Borrower's present and future
letters of credit, notes, drafts, instruments, documents, leases, and chattel
paper, and Borrower's books relating to any of the foregoing.

         "Obligations" means all loans, advances, debts, principal, interest
(including any interest which, but for the provisions of the United States
Bankruptcy Code, would have accrued), premiums, liabilities (including all
amounts charged to Borrower's loan account pursuant to any agreement
authorizing FINOVA to charge Borrower's loan account), obligations, fees
(including early termination fees), lease payments, guaranties, covenants,
and duties owing by Borrower to FINOVA of any kind and description (whether
pursuant to or evidenced by the Loan Documents, by any note or other
instrument, or by any other agreement between FINOVA and Borrower, and
whether or not for the payment of money), whether direct or indirect,
absolute or contingent, due or to become due, now existing or hereafter
arising, and including any debt, liability, or obligation owing from Borrower
to others which FINOVA may have obtained by assignment or otherwise, and
further including all interest not paid when due and all FINOVA Expenses
which Borrower is required to pay or reimburse by the Loan Documents, by law,
or otherwise.

         "Overadvance" has the meaning set forth in SECTION 2.3.

         "PBGC" means the Pension Benefit Guarantee Corporation.

         "Plan" means any plan described in ERISA Section 3(2) maintained for
employees of Borrower or any ERISA Affiliate, other than a Multiemployer plan.

         "Prohibited Transaction" means any transaction described in Section
406 of ERISA, which is not exempt by reason of Section 408 of ERISA, and any
transaction, described in Section 4975(c) of the IRC, which is not exempt by
reason of Section 4975(c)(2) of the IRC.

         "Reportable Event" means a reportable event described in Section
4043 of ERISA or the regulations thereunder, a withdrawal from a plan
described in Section 4063 of ERISA, or a cessation of operations described in
Section 4068(f) of ERISA.

         "Term Note" has the meaning set forth in SECTION 2.2.

    1.2  ACCOUNTING TERMS. All accounting terms not specifically defined
herein shall be construed in accordance with GAAP. When used herein, the term
"financial statements" shall include the notes and schedules thereto.

                                      4
<PAGE>


              1.3  CODE. Any terms used in this Agreement, which are defined
in the Code, shall be construed and defined as set forth in the Code unless
otherwise defined herein.

              1.4  CONSTRUCTION.  Unless the context of this Agreement
clearly requires otherwise, references to the plural include the singular, to
the singular include the plural. The words "hereof," "herein," "hereby,"
"hereunder," and similar terms in this Agreement refer to this Agreement as a
whole and not to any particular provision of this Agreement. Section,
sub-section, clause, and exhibit references are to this Agreement unless
otherwise specified.

              1.5  EXHIBITS.  All of the exhibits attached to this Agreement
shall be deemed incorporated herein by reference.

         2.   LOANS; INTEREST RATE AND OTHER CHARGES

              2.1  REVOLVING ADVANCES.  Subject to the terms and conditions
of this Agreement, FINOVA agrees to make revolving advances to Borrower in an
amount not to exceed the Borrowing Base. For purposes of this Agreement
"Borrowing Base" shall mean the sum of:

                  (a) An amount equal to the lesser of:
(I) SEVENTY FIVE PERCENT (75%) of the amount of Eligible Accounts; and (II)
an amount equal to Borrower's cash collections for the immediately preceding
forty-five (45) day period; plus

                  (b) An amount equal to the least of:
(I) TWENTY FIVE PERCENT (25%) of the amount of Eligible Inventory, (II) the
outstanding balance of advances against Eligible Accounts and (III) FOUR
HUNDRED THOUSAND AND 00/100 DOLLARS ($400,000.00) evidenced by a Secured
Promissory Note dated May 15, 1998.

                   FINOVA shall have no obligation to make advances hereunder
to the extent they would cause the outstanding balance of revolving advances
under this SECTION 2.1 to exceed a maximum amount of ONE MILLION FOUR HUNDRED
THOUSAND AND 00/100 DOLLARS ($1,400,000.00). FINOVA is authorized to make
advances under this Agreement based upon telephonic or other instructions
received from anyone purporting to be an officer, employee or representative
of Borrower, or without instructions if in FINOVA's discretion such advances
are necessary to meet Obligations. FINOVA will charge the amount of advances
made under this SECTION 2.1 to Borrower's loan account. Amounts borrowed
pursuant to this SECTION 2.1 may be repaid and reborrowed at any time during
the term of this Agreement so long as no Event of default has occurred and is
continuing.

              2.2  TERM LOAN.  FINOVA has agreed to make a term loan to
Borrower evidenced by, and repayable in accordance with, that certain Secured
Promissory Note, of even date herewith, by Borrower to the order of FINOVA,
in the original principal amount of N/A (the "Term Note"). Obligations owing
under the Term Note shall constitute Obligations, and the Term Note,
together with each amendment, extension, supplement, or replacement thereto,
shall be deemed to be a Loan Document.

              2.3  OVERADVANCES.  If, at any time or for any reason, the
amount of Obligations owed by Borrower to FINOVA, pursuant to SECTION 2.1 is
greater than the dollar or percentage limitation set forth in SECTION 2.1 (an
"overadvance"), Borrower shall immediately pay to FINOVA, in cash, the amount
of such excess, plus any fees owing pursuant to SECTION 2.7(b).

              2.4  INTEREST: RATE; PAYMENTS; AND CALCULATIONS.

                  (a) INTEREST RATE.  Except as specified to the contrary in
any Loan Document, the obligations shall bear interest, on the average Daily
Balance, at a rate of FIVE PERCENTAGE POINTS (5%) above the Base Rate.


                                     5

<PAGE>

                  (b) DEFAULT RATE.  All obligations shall bear interest,
from and after the occurrence of an Event of Default, at a rate of TEN
PERCENTAGE POINTS (10%) above the Base Rate.

                  (c) MINIMUM INTEREST.  In no event shall interest
chargeable hereunder be less than ONE percent (1.0%) per month, nor less than
THREE THOUSAND AND 00/100 DOLLARS ($3,000.00) per month.

                  (d) PAYMENTS. Interest hereunder shall be due and payable
on the first Business Day of each calendar month during the term hereof.
FINOVA shall, at its option, charge such interest and all FINOVA Expenses to
Borrower's loan account, which amounts shall thereafter accrue interest at the
rate then applicable hereunder.

                  (e) COMPUTATION.  The Base Rate as of this date is EIGHT
AND ONE QUARTER PERCENT (8.25%) per annum. In the event the Base Rate is
changed from time to time hereafter, the applicable rate of interest
hereunder shall be increased or decreased by an amount equal to the Base Rate
change on the effective date of such change. All interest chargeable under
the Loan Documents shall be computed on the basis of a three hundred sixty
(360) day year for the actual number of days elapsed.

              2.5  CREDITING PAYMENTS.  The receipt of any wire transfer of
funds, check, or other item of payment by FINOVA shall be immediately applied
to conditionally reduce Obligations, but shall not be considered a payment on
account unless such wire transfer is of immediately available federal funds
and is made to the appropriate deposit account of FINOVA or unless and until
such check or other item of payment is honored when presented for payment.
For interest calculation purposes, the receipt of any check, wire transfer,
or other item of payment by FINOVA shall be deemed to have been paid to
FINOVA FIVE (5) calendar days after the date FINOVA actually receives such
wire transfer or possession of such check or other item of payment.
Notwithstanding anything anything to the contrary contained herein, any wire
transfer or payment received by FINOVA after 10:00 a.m. Los Angeles time
shall be deemed to have been received by FINOVA as of the opening of business
on the immediately following business day.

              2.6  STATEMENT OF OBLIGATIONS.  FINOVA shall render statements
to Borrower of the Obligations, including all statements of principal,
interest, fees, and FINOVA Expenses owing, and such statements shall be
conclusively presumed to be correct and accurate and constitute an account
stated between Borrower and FINOVA unless, within thirty (30) days after
receipt thereof by Borrower, Borrower shall deliver to FINOVA by registered or
certified mail at its address specified herein above, written objection
thereto describing the error or errors, if any, contained in any such
statements.

              2.7  FEES.  Borrower shall pay to FINOVA the following fees:

                  (a) INITIAL FACILITY FEE.  Concurrently with the execution
and delivery of this Agreement, a fee (the "Initial Facility Fee") in the
amount of THREE THOUSAND AND 00/100 Dollars ($3,000.00). The Initial Facility
Fee shall be fully earned at the time of payment and non-refundable;

                  (b) OVERADVANCE FEE.  Upon the occurrence of any
Overadvance, a fee in an amount equal to one percent (1%) of the dollar
amount of such Overadvance, and every thirty (30) days thereafter that an
Overadvance, or any portion thereof, remains outstanding, a fee in an amount
equal to one percent (1%) of the highest dollar amount of Overadvance
existing on any day during the previous thirty (30) day period.

                  (c) ANNUAL FACILITY FEE.  On each anniversary date of the
effective date of this Agreement while any Obligations are outstanding, a fee
(the "Annual Facility Fee") in the amount equal to one percent (1%) of the
maximum amount of revolving advances allowable under SECTION 2.1. The Annual
Facility Fee shall be fully earned at the time of payment and non-refundable.

                                     6


<PAGE>

          (d) FINANCIAL EXAMINATION AND APPRAISAL. FINOVA's customary fee of
Five Hundred Dollars ($500) per day per examiner, plus out-of pocket expenses
for each financial analysis and examination of Borrower performed by FINOVA
or its agents.

          (e) COLLATERAL MANAGEMENT FEE. On the first day of each month while
this Agreement remains in effect, a fee (the "Collateral Management Fee") in
an amount equal to N/A% of Borrower's net sales for the preceding month. The
Collateral Management fee shall be based upon Borrower's sales as assigned/or
reported to FINOVA each month.

     2.8 TERM; AUTOMATIC RENEWAL. This Agreement shall become effective upon
acceptance by FINOVA and shall continue in full force and effect for a term
ending May 21, 2000 (the "Renewal Date") and shall be automatically renewed
for successive ONE (1) year periods thereafter, unless sooner terminated
pursuant to terms hereof. Either party may terminate this Agreement on the
Renewal Date or on any anniversary of the Renewal date by giving the other
party at least ninety (90) days prior written notice by registered or
certified mail, return receipt requested. Notwithstanding the foregoing,
FINOVA shall have the right to terminate this Agreement immediately and
without notice upon the occurrence of an Event of Default.

     2.9 EFFECT OF TERMINATION. On the date of termination, all Obligations
shall become immediately due and payable without notice or demand. No
termination of this Agreement, however, shall relieve or discharge Borrower
of Borrower's duties, Obligations, and covenants hereunder, and FINOVA's
continuing security interest in the Collateral shall remain in effect, until
all Obligations have been fully discharged and FINOVA's obligation to provide
advances hereunder is terminated. If Borrower has sent a notice of
termination pursuant to the provisions of SECTION 2.10, but fails to pay all
Obligations as of the date set in said notice, then FINOVA may, but shall not
be required to, renew this Agreement for an additional term of one (1) years.

     2.10 EARLY TERMINATION BY BORROWER. Notwithstanding the provisions of
SECTION 2.8 which allow termination of this Agreement by Borrower only on the
Renewal Date and certain anniversaries thereof, at any time subsequent to the
expiration of the initial year of this Agreement, Borrower has the option, on
ninety (90) days prior written notice to FINOVA, to terminate this Agreement
on a date other than an anniversary of the effective date by paying to
FINOVA, in cash, the Obligations together with all accrued and unpaid
interest and expense and a prepayment penalty of Fifteen Thousand Dollars
($15,000.00).

     2.11 TERMINATION UPON EVENT OF DEFAULT. If FINOVA terminates this
Agreement upon the occurrence of an Event of Default, in view of the
impracticability and extreme difficulty of ascertaining actual damages and by
mutual agreement of the parties as to a reasonable calculation of FINOVA's
lost profits as a result thereof, Borrower shall pay to FINOVA upon the
effective date of such termination, a fee ("Early Termination Fee") in an
amount equal to THE MINIMUM INTEREST DUE FOR THE REMAINING TERM OF THE
AGREEMENT. The Early Termination Fee shall be presumed to be the amount of
damages sustained by FINOVA as the result of the early termination and
Borrower agrees that it is reasonable under the circumstances currently
existing. The Early Termination Fee provided for in this SECTION 2.11 shall
be deemed included in the Obligations.

   3. SECURITY

     3.1 GRANT OF SECURITY INTEREST. Borrower hereby grants to FINOVA a
continuing security interest in all presently existing and hereafter acquired
or arising Collateral in order to secure prompt repayment of any and all
Obligations and in order to secure prompt performance by Borrower of each of
its covenants and duties under the Loan Documents. FINOVA's security interest
in the Collateral shall attach to all Collateral without further act on the
part of FINOVA or Borrower.

                                      7
<PAGE>

     3.2 NEGOTIABLE COLLATERAL. In the event that any Collateral, including
proceeds, is evidenced by or consists of Negotiable Collateral, Borrower
shall, immediately upon the request of FINOVA, endorse and assign such
Negotiable Collateral to FINOVA and deliver physical possession of such
Negotiable Collateral to FINOVA.

     3.3 COLLECTION OF ACCOUNTS, NEGOTIABLE COLLATERAL. FINOVA or FINOVA's
designee may, at any time: (a) notify customers or account debtors of
Borrower that the Accounts or Negotiable Collateral have been assigned to
FINOVA or that FINOVA has a security interest herein; (b) require Borrower to
establish a lock-box or other restricted account satisfactory to FINOVA for
the collection of Accounts; and (c) collect the accounts and Negotiable
Collateral directly and charge the collection costs and expenses to
Borrower's loan account; but, unless and until FINOVA does so or gives
Borrower other written instruction, Borrower shall collect all Accounts and
Negotiable Collateral for FINOVA, receive in trust all payments thereon as
FINOVA's trustee, and immediately deliver said payments to FINOVA in their
original form as received from the account debtor.

     3.4 DELIVERY OF ADDITIONAL DOCUMENTATION REQUIRED. Borrower shall
execute and deliver to FINOVA, prior to or concurrently with Borrower's
execution and delivery of this Agreement and at any time thereafter at the
request of FINOVA, all financing statements, continuation financing
statements, fixture filings, security agreements, assignments, endorsements
of certificates of title, applications for title, affidavits, reports,
notices, schedules of accounts, letters of authority, and all other documents
that FINOVA may reasonably request, in form satisfactory to FINOVA, to
perfect and maintain perfected FINOVA security interests in the Collateral
and in order to fully consummate all of the transactions contemplated under
the Loan Documents.

     3.5 POWER OF ATTORNEY. Borrower hereby irrevocably makes, constitutes,
and appoints FINOVA (and any of FINOVA'S officers, employees, or agents
designated by FINOVA) as Borrower's true and lawful attorney, with power to:
(a) sign the name of Borrower on any of the documents described in SECTION
3.4 or on any other similar documents to be executed, recorded, or filled in
order to perfect or continue perfected FINOVA's security interest in the
Collateral; (b) sign Borrower's name on any invoice or bill of lading
relating to any Account, drafts against account debtors, schedules and
assignments of Accounts, verifications of Accounts, and notices to account
debtors; (c) send requests for verification of Accounts; (d) endorse
Borrower's name on any checks, notes, acceptances, money orders, drafts, or
other forms of payment or security that may come into FINOVA's possession;
(e) notify the post office authorities to change the address for delivery of
Borrower's mail to an address designated by FINOVA, to receive and open all
mail addressed to Borrower, and to retain all mail relating to the Collateral
and forward all other mail to Borrower; (f) make, settle, and adjust all
claims under Borrower's policies of insurance and make all determinations and
decisions with respect to such policies of insurance; and (g) settle and
adjust disputes and claims respecting the accounts directly with account
debtors, for amounts and upon terms which FINOVA determines to be reasonable,
and FINOVA may cause to be executed and delivered any documents and releases
which FINOVA determines to be necessary. The appointment of FINOVA as
Borrower's attorney, and each and every one of FINOVA's rights and powers,
being coupled with an interest, is irrevocable until all of the Obligations
have been fully repaid and performed and FINOVA's obligation to provide
advances hereunder is terminated.

     3.6 RIGHT TO INSPECT. FINOVA (through any of its officers, employees, or
agents) shall have the right, from time to time hereafter, during Borrower's
usual business hours, or during the usual business hours of any third party
having control over the records of Borrower, to inspect Borrower's books and
to check and test the Collateral in order to verify Borrower's financial
condition or the amount, quality, value, condition of, or any other matter
relating to, the Collateral.

   4. CONDITIONS OF CLOSING

     4.1 INITIAL ADVANCE. Borrower agrees and acknowledges that FINOVA has no
obligation to make the initial advance hereunder until such time as FINOVA
is fully satisfied that (a) it has all the

                                       8
<PAGE>

loan and related documents, properly authorized and executed by Borrower, (b)
it has a first secured position in the Collateral, and (c) all other closing
conditions reasonably required by FINOVA have been met.

              4.2  SUBSEQUENT ADVANCES. The obligation of FINOVA to make any
subsequent advance hereunder shall be subject to the further conditions
precedent that, on and as of the date of such advance: (a) the
representations and warranties of Borrower set forth in this Agreement shall
be accurate, before and after giving effect to such advance and to the
application of any proceeds thereof; (b) no Event of Default and no event
which, with notice or passage of time or both, would constitute an Event of
Default has occurred and is continuing, or would result from such advance or
from the application of any proceeds thereof; (c) no material adverse change
has occurred in the Borrower's business, operations, or financial condition,
or in the condition of the Collateral or other assets of Borrower or in the
prospect of repayment of the Obligations; and (d) FINOVA shall have received
such other approvals, opinions or documents as FINOVA shall reasonably
request.

         5.   REPRESENTATION AND WARRANTIES

              Borrower represents and warrants as follows:

              5.1  NO PRIOR ENCUMBRANCES. Borrower has good and indefeasible
title to the Collateral, free and clear of liens, claims, security interest,
or encumbrances (except as held by FINOVA and except as may be specifically
consented to, in advance and in writing, by FINOVA).

              5.2  BONA FIDE ACCOUNTS. The Accounts are, and at all times
hereafter shall be, bona fide existing obligations created by the sale and
delivery of Inventory or the rendition of services to account debtors in the
ordinary course of Borrower's business, unconditionally owed to Borrower
without defenses, disputes, offsets, counterclaims, or rights of return or
cancellation. The property giving rise to such Accounts has been delivered to
the account debtor or to the account debtor's agent for immediate shipment to
and unconditional acceptance by the account debtor. Borrower has not, and at
all times hereafter, shall not have, received notice of actual or imminent
bankruptcy, insolvency, or financial embarrassment of any account debtor at
the time an Account due from such account debtor is assigned to FINOVA.

              5.3  MERCHANTABLE INVENTORY AND INVENTORY RECORDS. All
Inventory is now and at all times hereafter shall be of good and marketable
quality, free from defects. Borrower now keeps and hereafter at all times
shall keep, correct and accurate records itemizing and describing the kind
type, quality and quantity of the Inventory, and Borrower's cost therefor.

              5.4  LOCATION OF INVENTORY AND EQUIPMENT. The Inventory and
Equipment is not now and shall not at any time hereafter be stored with a
bailee, warehouseman, or similar party without FINOVA's prior written
consent. Borrower shall keep the Inventory and Equipment only at the
following location(s):
  428, 1434, 1444, 1460, 1470, 1500, AND 1516 SANTA ANITA AVENUE, SOUTH EL
  MONTE, CA 91733 AND 1425 AND 1427 LIDCOMBE AVENUE, SOUTH EL MONTE, CA 91733

              5.5  LOCATION OF PRINCIPAL PLACE OF BUSINESS/CHIEF EXECUTIVE
OFFICE/RESIDENCE. The chief executive office or residence of Borrower is at
the address indicated in the first paragraph of this Agreement and Borrower
covenants and agrees that it will not, without thirty (30) days prior written
notification to FINOVA, relocate such principal place of business, chief
executive office, or residence.

              5.6  DUE ORGANIZATION QUALIFICATION. If Borrower is a
corporation it is and shall at all times hereafter be duly organized and
existing and in good standing under the laws of the state of its
incorporation and qualified and licensed to do business in, and in good
standing in, any state in which the conduct of its business or its ownership
of property requires that it be so qualified; if Borrower is a partnership,
or limited liability company, it is and shall at all times hereafter be duly
organized and existing

                                     9

<PAGE>

and in good standing under the laws of the state of its organization and
qualified and licensed to do business in, and in good standing in, any state
in which the conduct of its business or the ownership of property requires
that its be so qualified.

              5.7  DUE AUTHORIZATION; NO CONFLICT. The execution, delivery,
and performance of the Loan Documents are within Borrower's corporate,
partnership, trust, limited liability company or personal powers, as the case
may be, have been duly authorized, and are not in conflict with nor
constitute a breach of any provision contained in Borrower's Articles or
Certificate of Incorporation, By-laws, or any operating agreement,
partnership or trust agreement pertaining to Borrower, nor will they
constitute an event of default under any material agreement to which Borrower
is now or may hereafter become a party.

              5.8  LITIGATION. There are no actions or proceedings pending by
or against Borrower before any court or administrative agency and Borrower
does not have knowledge or belief of any pending, threatened, or imminent
litigation, governmental investigations, or claims, complaints, actions, or
prosecutions involving Borrower or any guarantor of the Obligations, except
for ongoing collection matters in which Borrower is the plaintiff. If any of
the forgoing arises during the term of this Agreement, Borrower shall
promptly notify FINOVA in writing.

              5.9  NO MATERIAL ADVERSE CHANGE IN FINANCIAL STATEMENTS. All
financial statements relating to Borrower or any guarantor of the Obligations
which have been or may hereafter be delivered by Borrower to FINOVA have been
prepared in accordance with GAAP and fairly present Borrower's financial
condition as of the date thereof and Borrower's result of operations for the
period then ended. There has been no material adverse change in the financial
condition of Borrower or any guarantor since the date of the most recent of
such financial statements submitted to FINOVA.

              5.10 SOLVENCY. Borrower is now and shall be at all times
hereafter solvent and able to pay its debts (including trade debts) as they
mature.

              5.11 ERISA. None of Borrower, any ERISA Affiliate, or any plan
is or has been in violation of any of the provisions of ERISA, any of the
qualification requirements of IRC Section 401(a), or any of the published
interpretations there under. No notice of intent to terminate a Plan has been
filed under Section 4041 of ERISA, nor has any Plan been terminated under
Section 4041(e) of ERISA. The PBGC has not instituted proceedings to
terminate, or appoint a trustee to administer, a plan an no event has
occurred of condition exists which might constitute grounds under Section
4042 of ERISA for the termination of, or the appointment of a trustee to
administer, any Plan. Neither Borrower nor any ERISA Affiliate would be
liable for any amount pursuant to Section 4062, 4063, or 4064 of ERISA if all
Plans terminated as of the most recent valuation dates of such Plans. Neither
Borrower nor any ERISA Affiliate have: withdrawn from a "multiple employer
plan" during a plan year for which it was a substantial employer, as defined
in Section 4001(a)(2) of ERISA; or failed to make a payment to a plan
required under Section 302(f)(1) of ERISA such that security would have to be
provided pursuant to Section 307 of ERISA. No lien upon the assets of
Borrower has arisen with respect to any plan. No Prohibited Transaction or
Reportable Event has occurred with respect to Plan. Neither Borrower nor any
ERISA Affiliate has incurred any withdrawal liability with respect to any
Multiemployer Plan. Borrower and each ERISA Affiliate have made all
contributions required to be made by them to any plan or Multiemployer Plan
when due. There is no accumulated funding deficiency in any Plan, whether or
not waived.

              5.12 ENVIRONMENTAL CONDITION. None of Borrower's properties or
assets has ever been used by Borrower or, to the best of Borrower's
knowledge, by previous owners or operators in the disposal of, or to
produce, store, handle, treat, release, or transport, any hazardous waste or
hazardous substance. None of Borrower's properties or assets has ever been
designed or identified in any manner pursuant to any environmental protection
statute as a hazardous waste or hazardous substance disposal site, or a
candidate for closure pursuant to any environmental protection statute. No
lien arising under any environmental protection statute has attached to any
revenues or to any real personal property owned by Borrower. Borrower has not
received a summons, citation, notice, or directive from the Environmental
Protection

                                     10

<PAGE>

Agency or any other federal or state governmental agency concerning any
action or omission by Borrower resulting in the releasing, or otherwise
disposing of hazardous waste or hazardous substances into the environment.

         5.13 RELIANCE BY FINOVA; CUMULATIVE. Each warranty, representation,
and agreement contained in this Agreement shall be automatically deemed
repeated with each advance and shall be conclusively presumed to have been
relied on by FINOVA regardless of any investigation made or information
possessed by FINOVA. The warranties, representations, and agreements set
forth herein shall be cumulative and in addition to any and all other
warranties, representations, and agreements which Borrower shall now or
hereafter give, or cause to be given, to FINOVA.

         5.14 YEAR 2000 REPRESENTATIONS & WARRANTIES. Borrower has taken all
action necessary to assure that there will be no material adverse change to
Borrower's business by reason of the advent of the year 2000, including
without limitation that all computer-based systems, embedded microchips and
other processing capabilities effectively recognize and process dates after
April 1, 1999.

     6.  COVENANTS

         6.1   AFFIRMATIVE COVENANTS. Borrower covenants and agrees that, so
long as any credit hereunder shall be available and until payment in full of
the Obligations, and unless FINOVA shall otherwise consent in writing,
Borrower shall do all of the following:

         6.1.1 ACCOUNTING SYSTEM. Borrower at all times hereafter shall
maintain a standard and modern system of accounting in accordance with GAAP
with ledger and account cards or computer tapes, disks, printouts, and
records pertaining to the Collateral which contain information as may from
time to time be requested by FINOVA. Borrower shall also keep proper books of
Accounts showing all Sales, claims, and allowances on its inventory.

         6.1.2 COLLATERAL REPORTS. Borrower shall, deliver to FINOVA, no
later than the tenth (10th) day of each month during the term of this
Agreement, a detailed aging, by total, of the accounts, a reconciliation
statement, and a summary aging, by vendor, of all accounts payable and any
book overdraft. Original sales invoices evidencing daily sales shall be
mailed by Borrower to each account debtor with a copy to FINOVA, and, at
FINOVA's direction, the invoices shall indicate on their face that the
Account has been assigned to FINOVA and that all payments are to be made
directly to FINOVA. Borrower shall deliver to FINOVA, as FINOVA may from time
to time require, collection reports, sales journals, invoices, original
delivery receipts, customer's purchase orders, shipping instructions, bills
of lading and other documentation respecting shipment arrangements. Absent
such a request by FINOVA, copies of all such documentation shall be held by
Borrower as custodian for FINOVA.

         6.1.3 ASSIGNMENTS OF ACCOUNTS. Borrower shall provide FINOVA with
schedules describing all Accounts and shall execute and deliver to FINOVA
assignments of all Accounts. Borrower's failure to execute and deliver such
schedules or assignments shall not affect or limit FINOVA's security interest
or other rights in and to the Accounts.

         6.1.4 FINANCIAL STATEMENTS, REPORTS, CERTIFICATES. Borrower agrees
to deliver to FINOVA: (a) as soon as available, but in any event within
forty-five (45) days after the end of each fiscal quarter during each of
Borrower's fiscal years, a company prepared balance sheet, income statement
and cash flow statement covering Borrower's operations during such period;
and (b) as soon as available, but in any event within one hundred twenty
(120) days after the end of each of Borrower's fiscal years, financial
statements of Borrower for each such fiscal year, reviewed by independent
certified public accountants acceptable to FINOVA and certified, without any
qualifications, by such accountants to have been prepared in accordance with
GAAP, consistently applied, together with a certificate of such accountants
addressed to FINOVA stating that such accountants do not have knowledge of
the existence of any event or condition constituting an Event of Default.
Such reviewed financial statements shall include a balance sheet, profit

                                      11
<PAGE>

and loss statement, and cash flow statement, and such accountants' letter to
management. Borrower shall have issued written instructions to its
independent certified public accountants, authorizing them to communicate
with FINOVA and to release to FINOVA whatever financial information
concerning Borrower that FINOVA may request. If Borrower is a parent company
of one or more subsidiaries, or affiliates, or is a subsidiary or affiliate
of another company, then, in addition to the financial statement referred to
above, Borrower agrees to deliver financial statements prepared on a
consolidating basis so as to present Borrower and each such related entity
separately, and on a consolidated basis.

         Together with the above, Borrower shall also deliver to FINOVA any
other report reasonably requested by FINOVA relating to the Collateral and
the financial condition of Borrower.

         Each month Borrower shall deliver to FINOVA a certificate signed by
its chief financial officer to the effect that: (a) all reports, statements,
or computer prepared information of any kind or nature delivered or caused to
be delivered to FINOVA hereunder have been prepared in accordance with GAAP,
consistently applied and fully and fairly present the financial condition of
Borrower; (b) Borrower is in timely compliance with all representations,
warranties, and covenants hereunder; and (c) on the date of delivery of such
certificate to FINOVA there does not exist any condition or event which
constitutes an Event or Default.

         Borrower hereby irrevocably authorizes and directs all auditors,
accountants, or other third parties to deliver to FINOVA, at Borrower's
expense, copies of Borrower's financial statements, papers related thereto,
and other accounting records of any nature in their possession, and to
disclose to FINOVA any information they may have regarding Borrower's
business affairs and financial conditions.

         6.1.5 TAX RETURNS, RECEIPTS. Borrower agrees to deliver to FINOVA
copies of Borrower's future federal income tax returns and any amendments
thereto, within thirty (30) days of the filing thereof with the Internal
Revenue Service.

         6.1.6 GUARANTOR REPORTS. Borrower agrees to cause all guarantors of
any of the Obligations to deliver their annual financial statements and
copies of all federal income tax returns as soon as the same are available
and in any event no later than thirty (30) days after the same are required
to be filed by law.

         6.1.7 DESIGNATION OF INVENTORY AND RETURNS. Borrower shall now and
from time to time hereafter, but not less frequently than monthly, execute
and deliver to FINOVA a designation of Inventory specifying Borrower's cost
and the wholesale market value of Borrower's raw materials, work in process,
and finished goods, and further specifying such other information as FINOVA
may reasonably request. Returns and allowances, if any, as between Borrower
and its account debtors, shall be on the same basis and in accordance with
the usual customary practices of Borrower, as they exist at the time of the
execution and delivery of this Agreement. If at any time prior to the
occurrence of an Event of Default, any account debtor returns any Inventory
to Borrower, Borrower shall promptly determine the reason for such return
and, if Borrower accepts such return, issue a credit memorandum (with a copy
to be sent to FINOVA) in the appropriate amount to such account debtor.
Borrower shall promptly notify FINOVA of all returns and recoveries and of
all disputes and claims.

         6.1.8 TITLE TO EQUIPMENT. Upon FINOVA's request, Borrower shall
immediately deliver to FINOVA, properly endorsed, any and all evidences of
ownership of, certificates of title, or applications for title to any items
of Equipment.

         6.1.9 MAINTENANCE OF EQUIPMENT. Borrower shall keep and maintain the
Equipment in good operating condition and repair, make all necessary
replacements thereto so that the value and operating efficiency thereof shall
at all times be maintained and preserved. Borrower shall not permit any item
of Equipment to become a fixture to real estate or an possession to other
property, and the Equipment is now and shall at all times remain personal
property.

                                      12



<PAGE>

         6.1.10 TAXES. All assessments and taxes, whether real, personal, or
otherwise, due or payable by, or imposed, levied, or assessed against
Borrower or any of its property have been paid, and shall hereafter be paid
in full, before delinquency or before the expiration of any extension period.
Borrower shall make due and timely payment or deposit of all federal, state,
and local taxes, assessments, or contributions required of it by law, and
will execute and deliver to FINOVA, on demand, appropriate certificates
attesting to the payment or deposit thereof. Borrower will make timely
payment or deposit of all tax payments and withholding taxes required of it
by applicable laws, including, but not limited to, those laws concerning
F.I.C.A., and F.U.T.A., state disability, and local, state, and federal
income taxes, and will, upon request, furnish FINOVA with proof satisfactory
to FINOVA indicating that Borrower has made such payments or deposits.

          6.1.11 INSURANCE.

                 (a) Borrower, at its expense, shall keep the Collateral
insured against loss of damage by fire, theft, explosion, sprinklers, and all
other hazards and risks, and in such amounts, as ordinarily insured against
by other owners in similar businesses. Borrower shall also maintain business
interruption, public liability, product liability, and property damage
insurance relating to Borrower's ownership and use of the Collateral.

                 (b) All such policies of insurance shall be in such form,
with such companies, and on such amounts as satisfactory to FINOVA. All such
policies of insurance (except those of public liability and property damage)
shall contain a 438BFU lender's loss payable endorsement, or an equivalent
endorsement in a form satisfactory to FINOVA, showing FINOVA as sole loss
payee thereof, and shall contain a waiver of warranties, and shall specify
that, the insurer must give at least ten (10) days notice to FINOVA before
canceling its policy for any reason. Borrower shall deliver to FINOVA
certified copies of such policies of insurance and evidence of the payments
of all premiums therefor. All proceeds payable under any such policy shall be
payable to FINOVA to be applied on account of the Obligations.

         6.1.12 FINOVA EXPENSES. Borrower shall immediately and without
demand reimburse FINOVA for all sums expended by FINOVA which constitute
FINOVA Expenses and Borrower hereby authorizes and approves all advances and
payments by FINOVA for items constituting FINOVA Expenses.

         6.1.13 YEAR 2000 COVENANTS. Borrower shall take all action necessary
to assure that there will be no material adverse change to Borrower's
business by reason of the advent of the year 2000, including without
limitation that all computer-based systems, embedded microchips and other
processing capabilities effectively recognize and process dates after April 1,
1999. At FINOVA's request, Borrower shall provide to FINOVA assurance
reasonably acceptable to FINOVA that Borrower's computer-based systems,
embedded microchips and other processing capabilities are year 2000
compatible.

         6.2 NEGATIVE COVENANTS. Borrower covenants and agrees that, so long
as any credit hereunder shall be available and until payment in full of the
Obligations, Borrower will not do any of the following without FINOVA's prior
written consent:

         6.2.1 EXTRAORDINARY TRANSACTIONS AND DISPOSAL OF ASSETS. Enter into
any transaction not in the ordinary and usual course of Borrower's business,
including but not limited to, the sale, lease, or other disposition of,
moving, relocation, or transfer, whether by sale or otherwise, of any of
Borrower's assets (other than sales of Inventory in the ordinary and usual
course of Borrower's business as presently conducted), the incurrence of any
debts outside the ordinary and usual course of Borrower's business except for
renewals or extensions of existing debts, or the making of any advance or
loan except in the ordinary course of business as presently conducted, or the
suspension of Borrower's business.

         6.2.2 CHANGE NAME. Change Borrower's name, business structure, or
identity, or add any new fictitious name.

                                       13

<PAGE>

         6.2.3 MERGE, ACQUIRE. Acquire, merge, or consolidate with or into any
other business organization.

         6.2.4 GUARANTEE. Guarantee or otherwise become in any way liable
with respect to the obligations of any third party except by endorsement of
instruments or items of payment for deposit to the account of Borrower of
which are transmitted or turned over to FINOVA.

         6.2.5 RESTRUCTURE. Make any change in Borrower's financial structure
or in any of its business operations, or change the date of its fiscal year.

         6.2.6 PREPAYMENT. Prepay any existing indebtedness owing to any
third party.

         6.2.7 CHANGE OF OWNERSHIP. Cause, permit, or suffer any change,
direct or indirect, in Borrower's ownership in excess of ten percent (10%).

         6.2.8 CAPITAL EXPENDITURES. Make any plant or fixed capital
expenditure, or any commitment therefor, or purchase or lease any real or
personal property or replacement equipment subject to a purchase money
security interest, trust deed or lease, in excess of ONE HUNDRED FIFTY
THOUSAND AND 00/100 Dollars ($150,000.00) for any individual transaction or
where the aggregate amount of such transactions, in any fiscal year, is in
excess of ONE HUNDRED FIFTY THOUSAND AND 00/100 Dollars ($150,000.00).

         6.2.9 CONSIGNMENTS. Consign any Inventory, sell any goods on bill
and hold, or other unusual terms of sale.

         6.2.10 DISTRIBUTIONS. Make any distribution or declare or pay any
dividends (in cash or in stock) on, or purchase, acquire, redeem, or retire
any of Borrower's capital stock, of any class, whether now or hereafter
outstanding.

         6.2.11 ACCOUNTING METHODS. Modify or change its method of accounting
or enter into, modify, or terminate any agreement presently existing, or at
any time hereafter entered into with any third party accounting firm or
service bureau for the preparation or storage of Borrower's accounting
records without said accounting firm or service bureau agreeing to provide
FINOVA information regarding the Collateral or Borrower's financial
condition. Borrower waives the right to assert a confidential relationship,
if any, it may have with any accounting firm or service bureau in connection
with any information requested by FINOVA pursuant to or in accordance with
this Agreement, and agrees that FINOVA may contact directly any such
accounting firm or service bureau in order to obtain such information.

         6.2.12 INVESTMENTS. Directly or indirectly make or any beneficial
interest in (including stock, partnership interest, or other securities of),
or make any loan, advance, or capital contribution to, any corporation,
association, person, or entity, in excess on One Hundred Fifty Thousand and
00/100 Dollars ($150,000.00).

         6.2.13 TRANSACTIONS WITH AFFILIATES. Borrower will not directly or
indirectly enter into or permit to exist any material transaction with any
person or entity controlling, controlled by, or under common control (whether
by contract, ownership of voting securities, or otherwise) with Borrower
except for transactions which are in the ordinary course of Borrower's
business, upon fair and reasonable terms and which are fully disclosed to
FINOVA and no less favorable to Borrower than would be obtained in an arm's
length transaction with a non-affiliated person or entity.

                                       14

<PAGE>


         7.   DEFAULTS AND REMEDIES

              7.1  DEFAULTS. Any one or more of the following events shall
constitute an Event of Default by Borrower under this Agreement:

                  (a) If Borrower fails to pay when due and payable or when
declared due and payabl, any portion of the Obligations (whether of
principal, interest (including any interest which, but for the provisions of
the United States Bankruptcy Code, would have accrued on such accounts), fees
and charges due FINOVA, taxes, reimbursement of FINOVA Expenses, or
otherwise);

                  (b) If Borrower fails or neglects to perform, keep, or
observe any term, provision, condition, covenant, or agreement contained in
this Agreement, in any of the Loan Documents, or in any other present or
future agreement between Borrower and FINOVA;

                  (c) If there is a material impairment of the prospect of
repayment of any portion of the Obligations owing to FINOVA or a material
impairment of the value or priority of FINOVA's security interests in the
Collateral;

                  (d) If any material portion of Borrower's assets is
attached, seized, subjected to a writ or distress warrant, or is levied
upon, or comes into the possession of any judicial officer or assignee;

                  (e) If an Insolvency Proceeding is commenced by Borrower;

                  (f) If an Insolvency Proceeding is commenced against
Borrower;

                  (g) If Borrower is enjoined, restrained, or in any way
prevented by court order from continuing to conduct all or any material part
of its business affairs;

                  (h) If a notice of lien, levy, or assessment is filed or
recorded with respect to any of Borrower's assets by the United States
Government, or any department, agency, or instrumentality thereof, or by any
state, county, municipal, or other governmental agency, or if any taxes or
debts owing at any time hereafter to any one or more of such entities becomes
a lien, whether choate or otherwise, upon any of Borrower's assets and the
same is not paid on the payment date thereof;

                  (i) If a judgment or other claim becomes a lien or
encumbrance upon any material portion of Borrower's assets;

                  (j) If there is default in any material agreement to
which Borrower is a party with third parties resulting in a right by such
third parties, whether or not exercised, to accelerate the maturity of
Borrower's indebtedness;

                  (k) If Borrower makes any payment on account of
indebtedness which has been subordinated to the Obligations except to the
extent such payment is allowed under any subordination agreement entered
into with FINOVA;

                  (l) If any misstatement or misrepresentation exists now
or hereafter in any warranty, representation, statement, or report made to
FINOVA by Borrower or any officer, employee, agent, or director of Borrower,
or if any such warranty or representation is withdrawn by any officer or
director;

                  (m) If any guaranty of the Obligations is limited or
terminated by operation of law or by the guarantor thereunder, or any
guarantor becomes the subject of an Insolvency Proceeding;

                                     15

<PAGE>


                  (n) If a Prohibited Transaction or Reportable Event shall
occur with respect to a Plan which could have a material adverse effect on
the financial condition of Borrower; if any lien upon the assets of Borrower
in connection with any plan shall arise; if Borrower or any ERISA Affiliate
shall completely or partially withdraw from a Multiemployer Plan or a
Multiple Employer Plan of which Borrower or such ERISA Affiliate was a
substantial employer, and such withdrawal could, in the opinion of FINOVA,
have a material adverse effect on the financial condition of Borrower; if
Borrower or any of its ERISA Affiliates shall fail to make full payment when
due of all amounts which Borrower or any of its ERISA Affiliates may be
required to pay to any Plan or any Multiemployer plan as one or more
contributions thereto; if Borrower or any of its ERISA Affiliates creates or
permits the creation of any accumulated funding deficiency, whether or not
waived; or upon the voluntary or involuntary termination of any Plan which
termination could, in the opinion of FINOVA, have a material adverse effect
on the financial condition of Borrower, or Borrower shall fail to notify
FINOVA promptly and in any event within ten (10) days of the occurrence of
any event which constitutes an Event of Default under this clause or would
constitute such an Event of Default upon exercise of FINOVA's judgment; or

                  (o) If any writing, document, aging, certificate or other
evidence of the Accounts or Inventory shall be materially incomplete,
incorrect, or misleading at the time the same is furnished to FINOVA.

              7.2  REMEDIES. Upon the occurrence of an Event of Default
FINOVA may, at its election, without notice of its election and without
demand, do any one or more of the following, all of which are authorized by
Borrower;

                  (a) Declare all Obligations, whether evidenced by this
Agreement, by any of the other Loan Documents, or otherwise, immediately due
and payable;

                  (b) Cease advancing money or extending credit to or for
the benefit of Borrower under this Agreement, under any of the Loan
Documents, or under any other agreement between Borrower and FINOVA;

                  (c) Terminate this Agreement and any of the other Loan
Documents as to any future liability or Obligation of FINOVA, but without
affecting FINOVA's rights and security interest in the Collateral and without
affecting the Obligations;

                  (d) Settle or adjust disputes and claims directly with
account debtors for amounts and upon terms which FINOVA considers advisable,
and in such cases, FINOVA will credit Borrower's loan account with only the
net amounts received by FINOVA in payment of such disputed Accounts, after
deducting all FINOVA Expenses incurred or expended in connection therewith;

                  (e) Cause Borrower to hold all returned Inventory in
trust for FINOVA, segregate all returned Inventory from all other property of
Borrower or in Borrower's possession and conspicuously label said returned
Inventory as the property of FINOVA;

                  (f) Without notice to or demand upon Borrower or any
guarantor, make such payments and do such acts, as FINOVA considers necessary
or reasonable to protect its security interest in the Collateral. Borrower
agrees to assemble the Collateral if FINOVA so requires, and to make the
Collateral available to FINOVA as FINOVA may designate. Borrower authorizes
FINOVA to enter the premises where the Collateral is located, to take and
maintain possession of the Collateral, or any part of it, and to pay,
purchase, contest, or compromise any encumbrance, charge, or lien which in
FINOVA's determination appears to be prior or superior to its security
interest and to pay all expenses incurred in connection therewith. With
respect to any of Borrower's owned premises, Borrower hereby grants FINOVA a
license to enter into possession of such premises and to occupy the same,
without charge, for up to ninety (90) days in order to exercise any of
FINOVA's rights or remedies provided herein, at law, in equity, or otherwise;

                                      16

<PAGE>

                 (g) Set off and apply any and all balances and deposits held
by, or indebtedness at any time owing to or for the credit or the account of
Borrower by FINOVA without notice to Borrower (such notice being expressly
waived);

                 (h) Ship, reclaim, recover, store, finish, maintain, repair,
prepare for sale, advertise for sale, and sell (in the manner provided for
herein) the Collateral.  FINOVA is hereby granted a license or other right to
use, without charge, Borrower's labels, patents, copyrights, rights of use of
any name, trade secrets, trade names, trademarks, service marks, and
advertising matter, or any property of a similar nature, as it pertains to
the Collateral, in completing production of advertising for sale, and selling
any Collateral and Borrower's rights under all licenses and all franchise
agreements shall inure to FINOVA's benefit;

                 (i) Sell the Collateral at either a public or private sale,
or both, by way of one or more contracts or transactions, for cash or on
terms, in such manner and at such places (including Borrower's premises) as
FINOVA determines is commercially reasonable.  It is not necessary that the
Collateral be present at any such sale;

                 (j) FINOVA shall give notice of the disposition of the
Collateral as follows:

                     (1) FINOVA shall give the Borrower and each holder of a
security interest in the Collateral who has filed with FINOVA a written
request for notice, a notice in writing of the time and place of public sale,
or, if the sale is a private sale or some other disposition other than a
public sale is to be made of the Collateral, then the time on or after which
the private sale or other disposition is to be made;

                     (2) The notice shall be personally delivered or mailed,
postage prepaid, to Borrower as provided in Section 9.3 of this Agreement, at
least five (5) calendar days before the date fixed for the sale, or at least
five (5) calendar days before the date on or after which the private sale or
other disposition is to be made, unless the Collateral is perishable or
threatens to decline speedily in value.  Notice to persons other than
Borrower claiming an interest in the Collateral shall be sent to such
addresses as they have furnished to FINOVA;

                     (3) If the sale is to be a public sale, FINOVA shall
also give notice of the time and place by publishing a notice one time at
least five (5) calendar days before the date of the sale in a newspaper of
general circulation in the county in which the sale is to be held;

                 (k) FINOVA may credit bid and purchase at any public sale;
and

                 (l) Any deficiency, which exists after disposition of the
Collateral, as provided above will be paid immediately by Borrower.  Any
excess will be returned to Borrower, without interest and subject to the
rights of third parties, by FINOVA.

             7.3  REMEDIES CUMULATIVE. FINOVA's rights and remedies under this
Agreement, the Loan Documents, and all other agreements shall be cumulative.
FINOVA shall have all other rights and remedies not inconsistent herewith as
provided under the Code, by law, or in equity.  No exercise by FINOVA or one
right or remedy shall be deemed an election, and no waiver by FINOVA of any
Event of Default on Borrower's part shall be deemed a continuing waiver.  No
delay by FINOVA shall constitute a waiver, election, or acquiescence by it.

         8.  EXPENSES AND INDEMNITIES

             8.1  If Borrower fails to pay any monies (whether taxes,
assessments, insurance premiums, or otherwise) due to third persons or
entities, or fails to make any deposits or furnish any required proof of
payment or deposit, all as required under the terms of this Agreement, then,
to the extent that FINOVA determines that such failure by Borrower could have
a material adverse effect on FINOVA's

                                      17

<PAGE>

interests in the Collateral, in its discretion and without prior notice to
Borrower, FINOVA may do any or all of the following: (a) make payment of the
same or any part thereof; (b) set up such reserves in Borrower's loan account
as FINOVA deems necessary to protect FINOVA from the exposure created by such
failure; or (c) obtain and maintain insurance policies of the type discussed
in SECTION 6.1.11 of this Agreement, and take any action with respect to such
policies as FINOVA deems prudent.  Any amounts paid or deposited by FINOVA
shall constitute FINOVA Expenses, shall be immediately charged to Borrower's
loan account and become additional Obligations, shall bear interest at the
then applicable rate herein above provided, and shall be secured by the
Collateral.  Any payments made by FINOVA shall not constitute an agreement by
FINOVA to make similar payments in the future or a waiver by FINOVA of any
Event of Default under this Agreement.  FINOVA need not inquire as to, or
contest the validity of, any such expense, tax, security interest,
encumbrance, or lien and the receipt of the usual official notice for the
payment thereof shall be conclusive evidence that the same was validly due
and owing.

         9.  MISCELLANEOUS

            9.1  DEMAND; PROTEST; ETC. Borrower waives demand, protest, notice
of protest, notice of default or dishonor, notice of payment and nonpayment,
notice of any default, nonpayment at maturity, release, compromise,
settlement, extension, or renewal of accounts, documents, instruments,
chattel paper, and guarantees at any time held by FINOVA on which Borrower
may in any way be liable.

            9.2  FINOVA'S LIABILITY FOR INVENTORY OR EQUIPMENT. So long as
FINOVA complies with its obligations, if any, under Section 9207 of the Code;
FINOVA shall not in any way or manner be liable or responsible for: (a) the
safekeeping of the Collateral; (b) any loss or damage thereto occurring or
arising in any manner or fashion from any cause; (c) any diminution in the
value thereof; or (d) any act or default of any carrier, warehouseman,
bailee, forwarding agency, or other person whomsoever.  All risk of loss,
damage or destruction of the Collateral shall be borne by Borrower.

            9.3  NOTICES. Unless otherwise provided in this Agreement, all
notices or demands by any party relating to this Agreement or any other
agreement entered into in connection herewith shall be in writing and (except
for financial statements and other informational documents which may be sent
by first-class mail, postage prepaid) shall be personally delivered or sent
by registered or certified mail, postage prepaid, return receipt requested,
or by prepaid telex, TWX, telefacsimile, or telegram (with messenger delivery
specified) to Borrower or to FINOVA, as the case may be, at its addresses set
forth below:

                      IF TO BORROWER:  LEE PHARMACEUTICALS
                                       1444 SANTA ANITA AVENUE
                                       SOUTH EL MONTE, CA 91733
                                ATTN:  RONALD G. LEE, PRESIDENT

                        If to FINOVA:  FINOVA CAPITAL CORPORATION
                                       355 South Grand Avenue, #2400
                                       Los Angeles, California 90071
                                       Attention: Farhad Motia, Vice President

                      With a Copy to:

                                       Joseph R. D'Amore
                                       VP-Associate General Counsel
                                       FINOVA Capital Corporation
                                       1850 N. Central Ave, Suite 1141
                                       Phoenix, AZ 85002


                                      18

<PAGE>

     The parties hereto may change the address at which they are to receive
notices hereunder, by notice in writing in the foregoing manner given to the
other. All notices or demands sent in accordance with this SECTION 9.3, other
than notices by FINOVA in connection with Section 9504 or 9505 of the Code,
shall be deemed received on the earlier of the date of actual receipt or
three (3) calendar days after the deposit thereof in the mail. Borrower
acknowledges and agrees that notices sent by FINOVA in connection with
Sections 9504 or 9505 of the Code shall be deemed sent when deposited in the
mail or transmitted by telefacsimile or other similar method set forth above.

         9.4  CHOICE OF LAW AND VENUE; JURY TRIAL WAIVER. THE VALIDITY OF
THIS AGREEMENT, ITS CONSTRUCTION, INTERPRETATION, AND ENFORCEMENT AND THE
RIGHTS OF THE PARTIES HERETO SHALL BE DETERMINED UNDER, GOVERNED BY, AND
CONSTRUED IN ACCORDANCE WITH THE INTERNAL LAWS OF THE STATE OF CALIFORNIA,
WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAW. THE PARTIES AGREE THAT ALL
ACTIONS OR PROCEEDINGS ARISING IN CONNECTION WITH THIS AGREEMENT SHALL BE
TRIED AND LITIGATED ONLY IN THE STATE AND FEDERAL COURTS LOCATED IN THE
COUNTY OF LOS ANGELES, STATE OF CALIFORNIA OR AT THE SOLE OPTION OF FINOVA,
IN ANY OTHER COURT IN WHICH FINOVA SHALL INITIATE LEGAL OR EQUITABLE
PROCEEDINGS AND WHICH HAS SUBJECT MATTER JURISDICTION OVER THE MATTER IN
CONTROVERSY. EACH OF BORROWER AND FINOVA WAIVES, TO THE EXTENT PERMITTED
UNDER APPLICABLE LAW, ANY RIGHT EACH MAY HAVE TO ASSERT THE DOCTRINE OF FORUM
NON CONVENIENS OR TO OBJECT TO VENUE TO THE EXTENT ANY PROCEEDING IS BROUGHT
IN ACCORDANCE WITH THIS SECTION 9.4. BORROWER AND FINOVA HEREBY WAIVE THEIR
RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON
OR ARISING OUT OF ANY OF THE LOAN DOCUMENTS OR ANY OF THE TRANSACTIONS
CONTEMPLATED HEREIN, INCLUDING CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY
CLAIMS AND ALL OTHER COMMON LAW OR STATUTORY CLAIMS. BORROWER AND FINOVA EACH
REPRESENT THAT IT HAS REVIEWED THIS WAIVER AND EACH KNOWINGLY AND VOLUNTARILY
WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. IN
THE EVENT OF LITIGATION, A COPY OF THIS AGREEMENT MAY BE FILED AS A WRITTEN
CONSENT TO A TRIAL BY THE COURT.

         9.5  DESTRUCTION OF BORROWER'S DOCUMENTS. All documents, schedules,
invoices, agings, or other papers delivered to FINOVA may be destroyed or
otherwise disposed of by FINOVA three (3) months after they are delivered to
or received by FINOVA, unless Borrower requests, in writing, the return of
the said documents, schedules, invoices or other papers and makes
arrangements, at Borrower's expense, for their return.

         9.6  EFFECTIVENESS.  This Agreement shall be binding and deemed
effective when executed by Borrower and accepted and executed by FINOVA.

         9.7  SUCCESSORS AND ASSIGNS. This Agreement shall bind and inure to
the benefit of the respective successors and assigns of each of the parties;
PROVIDED, HOWEVER, that Borrower may not assign this Agreement or any rights
hereunder without FINOVA's prior written consent and any prohibited
assignment shall be absolutely void. No consent to an assignment by FINOVA
shall release Borrower from its Obligations. FINOVA may assign this Agreement
and its rights and duties hereunder. FINOVA reserves the right to sell,
assign, transfer, negotiate, or grant participations in all or any part of,
or any interest in FINOVA's rights and benefits hereunder. In connection
therewith, FINOVA may disclose all documents and information, which FINOVA
now or hereafter may have relating to Borrower or Borrower's business.

         9.8  SECTION HEADINGS. Heading and numbers have been set forth
herein for convenience only. Unless the contrary is compelled by the context,
everything contained in each paragraph applies equally to this entire Agreement.


                                       19

<PAGE>


         9.9  INTERPRETATION. Neither this Agreement nor any uncertainty or
ambiguity herein shall be construed or resolved against FINOVA or Borrower,
whether under any rule of construction or otherwise. On the contrary, this
Agreement has been reviewed by all parties and shall be construed and
interpreted according to the ordinary meaning of the words used so as to
fairly accomplish the purposes and intentions of all parties hereto.

         9.10 PUBLICITY. FINOVA is hereby authorized by the undersigned to
issue appropriate press releases and to cause a tombstone to be published
announcing the consummation of this transaction.

         9.11 SEVERABILITY OF PROVISONS. Each provision of this Agreement
shall be severable from every other provision of this Agreement for the
purpose of determining the legal enforceability of any specific provision.

         9.12 AMENDMENTS IN WRITING. This Agreement cannot be changed or
terminated orally. All prior agreements, understandings, representations,
warranties, and negotiations, if any, are merged into this Agreement.

         9.13 COUNTERPARTS. This agreement may be executed in any number of
counterparts and by different parties on separate counterparts, each of
which, when executed and delivered, shall be deemed to be an original, and
all of which, when taken together, shall constitute but one and the same
Agreement.

         Borrower and FINOVA have executed this Agreement of FINOVA's place
of business in Los Angeles, California.


                                              LEE PHARMACEUTICALS
                                              ------------------------
                                              a California corporation
                                              ----------------------------


                                          By: /s/ Ronald G. Lee
                                              ----------------------------
                                              Ronald G. Lee, President





                                              FINOVA CAPITAL CORPORATION
                                              ----------------------------
                                              a Delaware corporation
                                              ----------------------------



                                          By: /s/ Farhad Motia
                                              ----------------------------
                                              Farhad Motia, Vice President


                                       20



<PAGE>
                                                                   EXHIBIT 10.3

                            SECURED PROMISSORY NOTE



$400,000.00                                             Los Angeles, California
                                                               October 29, 1999



FOR VALUE RECEIVED, the undersigned hereby jointly and severally (if
applicable) promises to pay to FINOVA CAPITAL CORPORATION, a Delaware
Corporation, at 355 South Grand Avenue, Suite 2400, Los Angeles, California
90071, or at such other address as the holder may specify in writing, the
principal sum of FOUR HUNDRED THOUSAND AND 00/100 Dollars ($400,000.00) plus
interest as provided below.

This note shall bear interest at the rate of 14.25% per annum, computed on
the basis of a 360 day year for actual days elapsed.  This rate is based upon
the prime rate of interest of 8.25% the rate in effect as of this date.  The
prime rate of interest is the prime rate announced as being charged by
Citibank, N.A. (or any successor thereto), New York, New York, from time to
time.  In the event the prime rate is from time to time hereafter changed,
the rate of interest provided in this note shall be correspondingly changed.
For each month the rate of interest charged under this note shall be based
upon the average prime rate in effect during such month.  In no event shall
the rate of interest chargeable hereunder be less that 1.3% per month.

Principal shall be payable in twelve equal monthly installments of Eleven
Thousand One Hundred Eleven and 00/100 Dollars ($11,111.00) commencing
December 1, 1999 and continue thereafter on the 1st day of each month, plus
interest shall be payable monthly commencing December 1, 1999 and one final
installment on May 21, 2000 equal to all principal outstanding together with
all accrued and unpaid interest.

This note is secured by that certain Loan and Security Agreement
("Agreement") dated October 29, 1999 and is subject to all of the terms and
conditions thereof.  In the event of default under the Agreement, including
but not limited to, the failure to pay any installment of principal or
interest hereunder when due, the holder of this note may, at its election and
without notice to the undersigned, declare the entire balance hereof
immediately due and payable.

If any installment of principal or interest hereunder is not paid when due, the
holder shall have the following rights in addition to the rights set forth in
the preceding paragraph: (a) the right to add unpaid interest to principal and
to have such amount thereafter bear interest as provided in this note, and (b)
if any installment is more than ten days past due, the right to collect a
charge equal to the greater of $15.00 or five percent of the delinquent
payment.  This charge is the result of a reasonable endeavor by the
undersigned and the holder to estimate the holder's added costs and damages
resulting from the undersigned's failure to timely make payments under this
note; hence the undersigned agrees that the charge shall be presumed to be
the amount of the damage sustained by the holder since it is extremely
difficult to determine the actual amount necessary to reimburse the holder of
such damages.  If this note is not paid when due, the undersigned further
promises to pay all costs of collection, foreclosure fees and reasonable
attorneys' fees incurred by the holder whether or not suit is filed hereon.

<PAGE>

Provided the undersigned is not then in default hereunder or under any other
agreement with the holder of this note, this note may be prepaid at any time
prior to one year from the date hereof by paying the balance of principal
owing plus all accrued and unpaid interest and charges, together with a
prepayment charge of N/A on the amount prepaid.

Presentment for payment, notice of dishonor, protest, and notice of protest
are expressly waived.  This note cannot be changed, modified, amended or
terminated orally.

WAIVER OF TRIAL BY JURY. THE UNDERSIGNED, TO THE EXTENT IT MAY LEGALLY DO SO,
HEREBY EXPRESSLY WAIVES ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND,
ACTION, CAUSE OF ACTION, OR PROCEEDING ARISING UNDER OR WITH RESPECT TO THIS
NOTE, OR IN ANY WAY CONNECTED WITH, OR RELATED TO, OR INCIDENTAL TO, THE
DEALINGS OF THE PARTIES HERETO WITH RESPECT TO THIS NOTE OR THE TRANSACTIONS
RELATED THERETO, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND
IRRESPECTIVE OR WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE.  THE
UNDERSIGNED, TO THE EXTENT IT MAY LEGALLY DO SO, HEREBY AGREES THAT ANY SUCH
CLAIM, DEMAND, ACTION, CAUSE OF ACTION, OR PROCEEDING SHALL BE DECIDED BY A
COURT TRIAL WITHOUT A JURY AND THAT THE HOLDER OF THIS NOTE MAY FILE AN
ORIGINAL COUNTERPART OR A COPY OF THIS SECTION WITH ANY COURT AS WRITTEN
EVIDENCE OF THE CONSENT OF THE UNDERSIGNED TO THE WAIVER OF ITS RIGHT TO
TRIAL BY JURY.

IN WITNESS WHEREOF, this Note has been executed and delivered on the date
first set forth above.



LEE PHARMACEUTICALS
a California corporation




By:  /s/ Ronald G. Lee
     ---------------------------
     Ronald G. Lee, President


<PAGE>

                                                                   EXHIBIT 10.4

                            SECURED PROMISSORY NOTE




$400,000.00                                             Los Angeles, California
                                                               October 29, 1999





FOR VALUE RECEIVED, the undersigned hereby jointly and severally (if
applicable) promises to pay to FINOVA CAPITAL CORPORATION, a Delaware
Corporation, at 355 South Grand Avenue, Suite 2400, Los Angeles, California
90071, or at such other address as the holder may specify in writing, the
principal sum of FOUR HUNDRED THOUSAND AND 00/100 Dollars ($400,000.00) plus
interest as provided below.

This note shall bear interest at the rate of 14.25% per annum, computed on
the basis of a 360 day year for actual days elapsed. This rate is based upon
the prime rate of interest of 8.25% the rate in effect as of this date. The
prime rate of interest is the prime rate announced as being charged by
Citibank, N.A. (or any successor thereto), New York, New York, from time to
time. In the event the prime rate is from time to time hereafter changed, the
rate of interest provided in this note shall be correspondingly changed. For
each month the rate of interest charged under this note shall be based upon
the average prime rate in effect during such month. In no event shall the
rate of interest chargeable hereunder be less than 1.3% per month.

Principal shall be payable in twelve equal monthly installments of Eight
Thousand Three Hundred Dollars ($8,300.00) commencing December 1, 1999 and
continue thereafter on the 1st day of each month, plus interest shall be
payable monthly commencing December 1, 1999 and continue thereafter on the
1st day of each month, and one final installment on May 21, 2000 equal to all
principal outstanding together with all accrued and unpaid interest.

This note is secured by that certain Loan and Security Agreement
("Agreement") dated October 29, 1999 and is subject to all of the terms and
conditions thereof. In the event of default under the Agreement, including
but not limited to, the failure to pay any installment of principal or
interest hereunder when due, the holder of this note may, at its election and
without notice to the undersigned, declare the entire balance hereof
immediately due and payable.

If any installment of principal or interest hereunder is not paid when due,
the holder shall have the following rights in addition to the rights set
forth in the preceding paragraph: (a) the right to add unpaid interest to
principal and to have such amount thereafter bear interest as provided in
this note, and (b) if any installment is more than ten days past due, the
right to collect a charge equal to the greater of $15.00 or five percent of
the delinquent payment. This charge is the result of a reasonable endeavor by
the undersigned and the holder to estimate the holder's added costs and
damages resulting from the undersigned's failure to timely make payments
under this note; hence the undersigned agrees that the charge shall be
presumed to be the amount of damage sustained by the holder since it is
extremely difficult to determine the actual amount necessary to reimburse the
holder of such damages. If this note is not paid when due, the undersigned
further promises to pay all costs of collection, foreclosure fees and
reasonable attorneys' fees incurred by the holder whether or not suit is
filed hereon.

<PAGE>

Provided the undersigned is not then in default hereunder or under any other
agreement with the holder of this note, this note may be prepaid at any time
prior to one year from the date hereof by paying the balance of principal
owing plus all accrued and unpaid interest and charges, together with a
prepayment charge of N/A on the amount prepaid.

Presentment for payment, notice of dishonor, protest, and notice of protest
are expressly waived. This note cannot be changed, modified, amended or
terminated orally.

WAIVER OF TRIAL BY JURY. THE UNDERSIGNED, TO THE EXTENT IT MAY LEGALLY DO SO,
HEREBY EXPRESSLY WAIVES ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND,
ACTION, CAUSE OF ACTION, OR PROCEEDING ARISING UNDER OR WITH RESPECT TO THIS
NOTE, OR IN ANY WAY CONNECTED WITH, OR RELATED TO, OR INCIDENTAL TO, THE
DEALINGS OF THE PARTIES HERETO WITH RESPECT TO THIS NOTE OR THE TRANSACTIONS
RELATED THERETO, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND
IRRESPECTIVE OF WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE. THE
UNDERSIGNED, TO THE EXTENT IT MAY LEGALLY DO SO, HEREBY AGREES THAT ANY SUCH
CLAIM, DEMAND, ACTION, CAUSE OF ACTION, OR PROCEEDING SHALL BE DECIDED BY A
COURT TRIAL WITHOUT A JURY AND THAT THE HOLDER OF THIS NOTE MAY FILE AN
ORIGINAL COUNTERPART OR A COPY OF THIS SECTION WITH ANY COURT AS WRITTEN
EVIDENCE OF THE CONSENT OF THE UNDERSIGNED TO THE WAIVER OF ITS RIGHT TO TRIAL
BY JURY.

IN WITNESS WHEREOF, this Note has been executed and delivered on the date
first set forth above.



LEE PHARMACEUTICALS
a California corporation



By: /s/ Ronald G. Lee
    ------------------------
    Ronald G. Lee, President

<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          SEP-30-2000
<PERIOD-START>                             OCT-01-1999
<PERIOD-END>                               DEC-31-1999
<CASH>                                               6
<SECURITIES>                                         0
<RECEIVABLES>                                    1,145
<ALLOWANCES>                                     (157)
<INVENTORY>                                      2,407
<CURRENT-ASSETS>                                 4,014
<PP&E>                                           6,709
<DEPRECIATION>                                   6,211
<TOTAL-ASSETS>                                   8,134
<CURRENT-LIABILITIES>                            6,748
<BONDS>                                              0
                                0
                                          0
<COMMON>                                           413
<OTHER-SE>                                     (3,036)
<TOTAL-LIABILITY-AND-EQUITY>                     8,134
<SALES>                                          2,322
<TOTAL-REVENUES>                                 2,537
<CGS>                                            1,068
<TOTAL-COSTS>                                    2,321
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 216
<INCOME-PRETAX>                                     18
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                 18
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                        18
<EPS-BASIC>                                        .00
<EPS-DILUTED>                                      .00


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission